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OVERVIEW OF CANINE OSTEOARTHRITIS 
1. ANATOMY OF THE SYNOVIAL JOINT 
 
Joints can be divided into the three main categories of synovial, cartilaginous and 
fibrous joints depending on their degree of mobility (Piermattei et al. 2006; Liebich et 
al. 2007; Sjastaad et al. 2007). The clinically important joint diseases, such as 
osteoarthritis, affect mainly the synovial joints that have the highest range of motion 
(Piermattei  et  al.  2006).  Examples  of  the  synovial  joints  are  the  hip  and  elbow  joints  
(Sjastaad et al. 2007). Fibrous joints can be found for example between the bones of 
the skull in young animals, while the joints between the vertebrae are examples of the 
cartilaginous joints (Sjastaad et al. 2007). 
   All synovial joints, also known as the true joints, consist of a joint capsule, articular 
cartilage, subchondral bone and synovial fluid (Piermattei et al. 2006; Sjastaad et al. 
2007;Liebich et al. 2007). 
 
1.1. Joint capsule 
 
The two layers of the joint capsule are the outer fibrous layer and the inner layer also 
known as the synovial membrane (Liebich et al. 2007).  The nerves, blood vessels and 
lymphatic vessels are located between the fibrous capsule and the synovial membrane 
(Schulz 2007). 
     The inner surface of the joint capsule is lined by the synovium that contains the 
synoviocytes (Edwards 2011). There are two types of synoviocytes (Liebich et al. 2007). 
Type A synoviocytes resemble macrophages by clearing debris by phagocytosis while 
the type B synoviocytes resemble fibroblasts and produce hyaluronic acid, proteins 
and potentially degenerative enzymes (Liebich et al. 2007; Edwards 2011). 
 
1.2. Synovial fluid 
 
The joint cavity is filled with synovial fluid that is formed as a dialysate of plasma from 
the blood vessels of the synovial membrane (Schulz 2007). Synovial fluid contains 
hyaluronic acid, sugar, electrolytes and enzymes that are vital for the nutrition of the 
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cartilage (Liebich et al. 2007).  The hyaluronic acid in the synovial fluid lubricates the 
joint, acts as a shock absorber and decreases the friction caused by the joint 
movement (Venable 2008). 
 
1.3. Articular cartilage and subchondral bone 
 
The articular cartilage is a 1 to 5 mm thick layer of hyaline cartilage that facilitates the 
gliding movement of the joint, distributes mechanical loads and protects the 
underlying subchondral bone from injury (Schulz 2007; Sjastaad et al. 2007; Mobasheri 
2010).  The mechanically resilient extracellular matrix of hyaline cartilage consists 
mainly of the cartilage-specific type II collagen and aggregating proteoclycans 
(Mobasheri 2010; Garvican 2010). Proteoglycans consist of a protein core with 
covalently attached glycosaminoglycan side-chains (Bliss et al. 2012). Examples of 
glycosaminoglycans are keratin sulfate and chondroitin sulfate (Bliss et al. 2012). 
    Articular cartilage is joined with cancellous bone by subchondral bone which is a thin 
layer  next  to  the  epiphysis  (Liebich  et  al.  2007).   Subchondral  bone  acts  as  a  shock-
absorber as its interdigitated junction with cartilage helps to transform shear forces 
into  tensile  and  compressive  forces  (Garstang  et  al.  2006).   Subchondral  bone  also  
contains end arteries and veins that serve in the nutrition and waste product removal 
of articular cartilage (Garstang et al. 2006). 
       Despite its durability, the self-maintaining capacity and ability to response to injury 
of cartilage are very limited as it is metabolically quite inactive and lacks blood supply 
(Sjastaad et al. 2007; Schindler et al. 2011; Mobasheri et al. 2010). Articular cartilage 
also lacks nerve and lymph supply (Mobasheri et al. 2010; Schindler et al. 2011). 
Cartilage lesions that do not reach the subchondral bone do not usually repair 
spontaneously and the repair of full thickness lesions depends on the factors such as 
the size and location of the lesion (Koga et al. 2009). While small defects can be 
repaired with the production of hyaline cartilage, larger defects can only be repaired 
with the production of fibrous tissue or fibrocartilage that lacks the biochemical and 
biomechanical properties of hyaluronic cartilage (Koga et al. 2009). 
   The only cell type in cartilage, the chondrocyte, is solely responsible for the synthesis 
and turnover of the cartilage extracellular matrix (Mobasheri et al. 2010). 
Chondrocytes secrete macromolecular components such as collagen, 
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glycosaminoglycans and hyaluronic acid and modulate the extracellular matrix 
turnover and by this way maintain homeostatic synthesis and degradation of the 
extracellular matrix (Mortellaro 2003; Black et al 2008). The secretion of lytic and 
tissue-damaging mediators such as cytokines, free radicals, proteases and 
prostaglandins is controlled by anabolic and reparative substances such as growth 
factors and inhibitors of catabolic cytokines and inhibitors of degradative enzymes 
(Mortellaro 2003; Black et al 2008). 
     The major part of the nutrients reaches the articular cartilage by diffusion from the 
synovial fluid (Liebich et al. 2007; Garvican 2010). Some transport of nutrients to 
articular cartilage can also occur from the joint synovia or from the blood vessels of the 
bone marrow (Liebich et al. 2007; Garvican 2010). 
 
1.4. Additional structures 
 
The surrounding tendons provide external support for the joint (Schulz 2007). Joints 
also contain intracapsular, capsular or extracapsular ligaments that add to the stability 
of  the  joint  (Liebich  et  al.  2007).  In  addition  to  these,  in  some  joints  there  are  also  
fibrocartilagenous structures, such as the menisci in the knee joint, that further help to 
stabilize  the  joint  (Liebich  et  al.  2007).  Also  other  structures  facilitating  the  joint  
function, such as fat pads, can be found in certain joints (Schulz 2007). 
 
2. ARTHROPATHIES 
 
2.1. Classification of arthropathies 
      
Diseases affecting the joints, also known as arthropathies, can be divided into the two 
major categories of inflammatory and noninflammatory arthropathies based on the 
disease etiology (Schulz 2007). Inflammatory arthropathies can be further divided into 
the groups of immune-mediated, infective and crystal-induced disease processes 
(Innes 2012). The most common joint disease in dogs in the category of inflammatory 
arthropathies is immune-mediated nonerosive polyarthritis (IMPA) that is 
characterized by immune-complex deposition in the synovium resulting in synovitis 
and inflammation in the joint (Taylor 2009). 
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    Several developmental, degenerative, neoplastic and traumatic joint disorders fall in 
the category of non-inflammatory joint disorders (Taylor 2009). Some of the diseases 
in this category are osteoarthritis, coagulopathic arthritis and traumatic arthritis (Innes 
2012). Of these, osteoarthritis is the most common one, as it is the most common of 
all joint diseases in dogs (Taylor 2009; Innes 2012). 
 
2.2. Diagnostic approach to joint disease 
 
The anamnesis of an animal with a joint disease usually includes a history of lameness 
or abnormal gait (Taylor 2009). Inflammatory arthropathies might also cause signs of 
systemic illness such as fever and depression (Taylor 2009). Polyarthritis, meaning the 
concurrent inflammation of several joints, may not always cause obvious lameness but 
instead might lead to less specific signs such as decreased appetite, fever, weakness, 
stiffness and exercise intolerance (Schulz 2007). 
      A thorough physical examination should always be performed even if the 
anamnesis clearly points to an orthopedic problem. Physical examination might reveal 
other health problems that might be related to an orthopedic disease or influence the 
patient’s suitability for sedation or a certain treatment option. (Arthurs 2011.) 
     Orthopedic examination should be performed on all patients with a history of 
lameness, exercise intolerance, collapses or ataxia or that are recumbent (Arthurs 
2011). Abnormalities attributable to an arthropathy, in addition to lameness or 
abnormal gait, include changes in the range of motion, pain, instability and crepitation 
on the manipulation of the affected joints (Schuz 2007). Joint enlargement and heat 
might also be found along with asymmetrical musculature due to shifting of the weight 
to the unaffected side (Schulz 2007).  
     After localizing the problem to a joint by physical and orthopedic examination, 
further diagnostic tools include collecting the minimum database (complete blood 
count, serum biochemistry and urinalysis), radiography possibly accompanied by other 
imaging modalities such as computed tomography and magnetic resonance imaging 
and  possibly  a  synovial  fluid  analysis  and  culture  (Taylor  2009).  Synovial  membrane  
biopsy and immunologic and serologic testing might also be appropriate in certain 
cases (Taylor 2009). 
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    There should be no abnormal changes in the complete blood count (CBC), serum 
biochemistry and urinalysis in cases of non-inflammatory joint diseases, but for 
example certain infectious arthropathies may cause abnormal findings such as 
leukocytosis (Taylor 2009).  
   Radiographs should be taken in cases where there are abnormal findings on joint 
manipulation, such as pain, swelling, crepitation, instability or restricted range of 
motion (Taylor 2009).  Signs of a joint disease seen on radiographs include the 
increased volume of synovial fluid, changes in the width of the joint space, changes in 
the opacity of subchondral or perichondral bone, subchondral cyst formation, 
perichondral bone proliferation, also known as osteophyte formation, mineralization 
of the articular soft tissues or intra-articular mineralized fragments and abnormalities 
in the joint congruity (Allan 2007).   Abnormal findings on radiographs can be expected 
especially in cases of osteoarthritis, chronic septic arthritis and immune-mediated 
erosive arthritis (Taylor 2009). However, one should note that the radiographic 
abnormalities are usually non-specific and might not be seen until weeks to months 
after the onset of clinical signs (Taylor 2009). 
    When suspecting a joint disease, the most useful diagnostic test is synovial fluid 
analysis that should be performed when signs of joint disease are found during the 
previous diagnostic steps (Clements 2006; Taylor 2009). Synovial fluid analysis should 
also be performed in cases where polyarthritis or sepsis is suspected or when there are 
potential signs of immune-mediated joint disease such as fever of unknown origin 
(Clements 2006; Taylor 2009). 
     Synovial fluid analysis helps not only to confirm or rule out joint disease as a cause 
of lameness or other clinical signs, but it also helps to evaluate the treatment response 
in cases of previously diagnosed inflammatory joint diseases (Clements 2006). It is also 
useful in differentiating between different types of arthropathies as shown on the 
Table 1 (Schulz 2007; Taylor 2009).  
    The volume, colour, viscosity and cloudiness of synovial fluid are also evaluated. The 
normal synovial fluid is colorless or light yellow, viscous and clear (Clements 2006). 
Laboratory analysis provides information on the cytology and relative numbers of the 
different cell types (Clements 2006). 
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Table 1. Typical total and differential cell counts for canine synovial fluid in normal joints and    
in different joint diseases (Innes 2012). 
 
Condition Total cell count Percentage of 
mononuclear cells 
Percentage of 
neutrophils 
Normal  <2 × 109 /L 94-100 0-6 
Osteoarthritis 2-5 × 109 /L 88-100 0-12 
Rheumatoid 
arthritis 
8-38 × 109 /L 20-80 20-80 
Nonerosive IMPA 4-370 × 109 /L 5-85 15-95 
Infective arthritis 40-267 × 109 /L 1-10 90-100 
 
3. OSTEOARTHRITIS 
 
3.1. Overview 
 
Osteoarthritis (OA, also known as degenerative joint disease, hypertrophic arthritis, 
degenerative arthritis and osteoarthrosis) can be defined as a process of abnormal 
repair  and  progressive  loss  of  articular  cartilage  (Schulz  2007;  Garvican  2010).  
Osteoarthritis  affects  all  mammals  and  it  is  an  important  and  costly  disease  in  dogs,  
horses and humans (Venable 2008; Garvican 2010). It is a common cause of chronic 
pain  and  the  most  common  type  of  arthritis  in  dogs  as  it  has  been  estimated  that  
about 20 % of adult dogs suffer from it (Allan 2007; Innes 2012). Osteoarthritis is the 
most important chronic musculoskeletal disease in horses and a significant cause of 
economic  losses  in  the  equine  industry  (Van  Wereen  2010).  It  is  the  most  common  
arthropathy also in humans as it affects millions of people in the western countries 
(Mele 2007; Chevalier 2010). 
    The pathophysiological and clinical features of osteoarthritis as well as the 
treatment responses and the anatomy of stifle joint are very similar in dogs compared 
to humans. Thus the dog is the most commonly used animal model for the studies on 
osteoarthritis. (Cook 2010.) 
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3.2. Etiology 
 
Osteoarthritis can be divided into the primary or secondary forms based on whether or 
not an underlying cause can be identified (Schulz 2007). In primary, or idiopathic, 
osteoarthritis, which is more common in humans than in dogs, there is no known 
cause for the disease development (Schulz 2007; Innes 2012). Some of the factors that 
can  lead  to  the  development  of  secondary  osteoarthritis  are  alterations  in  the  joint  
biomechanics, such as joint instability and abnormal loading of the articular cartilage 
or disorders leading to the formation of abnormal cartilage (Schulz 2007; Innes 2012). 
Common causes of secondary osteoarthritis in dogs are hip dysplasia and cranial 
cruciate ligament rupture (Schulz 2007). 
      The risk factors of osteoarthritis can be divided into two major categories: systemic 
and local risk factors (Garstang 2006). Local factors such as prior joint trauma, 
overload, instability, muscle weakness and developmental abnormalities alter the 
biomechanical loading of affected joints (Garstang 2006; Schulz 2007). The role of 
systemic factors in the disease development is more obscure and less studied in dogs 
compared to humans (Innes 2012). Examples of systemic risk factors are genetic 
factors, high age, nutritional factors, gender and hormonal status (Garstang 2006; 
Innes 2012). In dogs no genes predisposing to the development of osteoarthritis have 
yet been identified (Innes 2012).  
     Obesity  is  an  important  risk  factor  that  is  likely  to  have  both  a  systemic  and  local  
component (Garstang 2006; Innes 2012). Increased load on the joint coupled with 
altered joint alignment was for a long time thought to be the only mechanism by which 
obesity predisposes to the development of osteoarthritis (Innes 2012; Sanderson 
2012). However, based on recent research the adipokines secreted by adipose tissue, 
such as tumor necrosis factor (TNF), interleukin-6 (IL-6) and leptin, are also likely to 
play a role in the pathogenesis of osteoarthritis by generating systemic low-level pro-
inflammatory  conditions  that  affect  the  joint  metabolism  (Innes  2012;  Sanderson  
2012). Indeed, maintaining optimal body condition has been shown to decrease the 
progression of osteoarthritis in dogs (Innes 2012). 
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3.3. Pathogenesis 
 
For a long time osteoarthritis was seen as a result of simple wear and tear, until about 
three decades ago, when the role of cellular mechanisms in the pathogenesis of 
osteoarthritis  was  recognized  (Evans  et  al.  2005).  Despite  this  discovery  and  the  
vigorous research the pathophysiology of osteoarthritis is still not fully understood but 
it is likely to involve a combination of mechanical, biological, biochemical, molecular 
and enzymatic processes (Chevalier & Kemta-Lepka 2010). 
       Although the hallmark of the disease process is abnormal repair and gradual 
degradation of articular cartilage, osteoarthritis causes changes also in all of the other 
structures of the synovial joint including the synovial membrane, synovial fluid and 
subchondral bone (Mateescu et al. 2008; Garvican et al. 2010; Innes 2012). Osteophyte 
formation is also typical in osteoarthritis and it is considered as an attempt to limit 
both movement and pain that occur in response to the chronic inflammation and local 
tissue damage (Mele et al 2007; Schulz 2007; Innes 2012).  In addition to articular 
structures, osteoarthritis also affects other tissues as the decreased use of the affected 
limb weakens the surrounding muscles, ligaments and tendons (Garstang et al. 2006; 
Innes 2012). 
       In osteoarthritis there is a relative overproduction of catabolic and pro-
inflammatory mediators to their inhibitors leading to a catabolic state in the articular 
cartilage and eventually to its progressive destruction (Mortellaro 2003; Black et al. 
2008). The release of degradation products from the extracellular matrix of articular 
cartilage due to mechanical or enzymatic destruction can cause the release of catabolic 
and pro-inflammatory mediators such as cytokines IL-1, IL-6 and TNF-?, nitric oxide 
and destructive enzymes by chondrocytes and synovial cells (Chevalier & Kemta-Lepka 
2010; Mobasheri & Henrotin 2010; Innes 2012). This initiates an inflammatory 
response that alters the normal balance of cartilage matrix degradation and repair 
(Chevalier & Kemta-Lepka 2010; Mobasheri & Henrotin 2010). The decreased synthesis 
of the inhibitors of the aforementioned pro-inflammatory mediators causes further 
damage to the articular cartilage (Schulz 2007; Innes et al. 2010a; Innes 2012). 
Diseased cartilage is more susceptible to mechanical stress and further damage and 
thus the vicious cycle of inflammation and cartilage destruction is initiated (Schulz 
2007). Grossly the deterioration of articular cartilage is initially seen as fibrillation of 
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the superficial layer of the joint cartilage that ultimately proceeds to deeper fissures 
eventually reaching the subchondral bone (Schulz 2007; Innes 2012). 
      The importance of the cellular mechanisms and inflammatory mediators in the 
pathogenesis of osteoarthritis has been pointed out in studies such as the one by Xu et 
al.  (2009)  that  investigated  the  effect  of  biological  factors  in  the  synovial  fluid  of  an  
osteoarthritic joint on normal articular cartilage. Osteoarthritis of the stifle joint was 
induced  surgically  and  confirmed  24  weeks  later  in  eight  dogs.  After  this,  an  elbow  
joint of each dog was injected with synovial fluid from the osteoarthritis stifle joint of 
the same dog while the other elbow was injected with the same volume of saline. The 
injections were performed once a week for 24 weeks. Significant morphological 
changes  in  the  articular  cartilage  of  the  elbow  joint  were  observed  48  after  the  
surgery. These changes included degeneration of chondrocytes and cartilage matrix 
along with changes in the superficial layer of the cartilage evaluated by electron 
microscope. Almost no differences in the articular cartilage between the saline 
injected joints and in the joints of the control group were noted.  
       Despite being classified as a non-inflammatory arthropathy, osteoarthritis involves 
synovial  inflammation,  the  degree  of  which  varies  across  different  synovial  sites  and  
over time (Schulz 2007; Chevalier & Kemta-Lepka 2010; Innes 2012). Synovitis is often 
associated with increased capillary permeability and subsequent leakage of serum 
proteins which leads to synovial edema and increased synovial fluid volume (Edwards 
2011). 
 
3.4. Diagnosis  
 
3.4.1. Anamnesis 
 
The  clinical  signs  of  osteoarthritis  are  similar  to  those  of  other  joint  disease  (Innes  
2012). The most common of these is lameness, but other complaints such as stiffness 
after  rest  and  reluctance  to  exercise  or  jump  are  also  common  (Schulz  2007;  Innes  
2012). Behavioral changes caused by pain are also possible and can be either overt or 
very subtle and thus easily missed (Hellyer et al. 2007; Innes 2012). The clinical signs 
can worsen over time or they can be intermittent with periods of disease flares (Innes 
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2012).  They  can  also  be  affected  by  external  factors  such  as  changes  in  exercise  or  
weather (Innes 2012). 
    Osteoarthritis can affect any joint and dogs of all sizes and breeds can be affected as 
they age (Rychel 2010). The dog might have a history of having a predisposing 
condition such as another type of arthritis, previous joint trauma, joint or patellar 
luxation, hip or elbow dysplasia or cranial cruciate ligament rupture (Schulz 2007). 
 
3.4.2. Minimum database 
 
As stated earlier, there are no abnormal findings in the complete blood count, serum 
biochemistry or urinalysis caused by osteoarthritis (Taylor 2009). However, collecting 
minimum database is useful for identifying possible concurrent diseases that might 
limit the therapy options. 
 
3.4.3. Clinical examination 
 
Lameness is a common finding in the clinical examination, unless the dog suffers from 
a bilateral condition in which case more subtle signs such as a continuous shifting of 
the weight while standing or shortened stride may be seen (Schulz 2007). Other signs 
such as muscle atrophy and abnormal changes in the palpation and manipulation of 
the affected joint such as joint swelling or effusion, capsular or extracapsular fibrosis, 
diminished range of motion, crepitus and pain can also be found (Innes 2012). 
     A predisposing condition such as a rupture of the cranial cruciate ligament or joint 
incongruity caused by trauma or angular limb deformity might also be identified during 
the clinical examination (Taylor 2009).  Systemic signs such as fever and depression 
that are common in inflammatory joint diseases do not accompany osteoarthritis 
(Taylor 2009). 
 
3.4.4. Radiography 
 
The radiographic changes of osteoarthritis vary depending on the stage of the disease 
process (Allan 2007). In the early stages of osteoarthritis there are typically no 
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radiographic findings but as the disease progresses radiographic changes become 
evident (Allan 2007). 
     The most readily recognizable radiographic change is osteophyte formation despite 
the fact that it is not pathognomonic for osteoarthritis (Allan 2007; Innes 2012). The 
osteophytes are formed in the articular margins and attachment sites of the joint 
capsule, tendons and ligaments (Marino & Loughin 2010). Osteophytes at the sites 
where a tendon or ligament attaches to bone are also known as enthesophytes (Allan 
2007). In the stifle joint osteophytes are most commonly found in the trochlear ridges, 
patella, fabella, attachment sites of the ligaments and the caudal tibial plateau (Marino 
&  Loughin  2010).  In  the  coxofemoral  joint  osteophytes  are  most  commonly  seen  on  
the cranial or caudal margins of the acetabulum and also in the femoral head and neck 
(Kapatkin et al. 2002). 
    Other common radiographic signs of osteoarthritis are the synovial fluid effusion 
and increased opacity, also known as sclerosis, of the subchondral bone (Allan 2007). 
In the stifle joint synovial effusion causes proximal displacement of the infrapatellar fat 
pad and caudal displacement of the joint capsule (Marino & Loughin 2010). 
   Changes  in  the  width  of  the  joint  space  are  also  possible  as  the  joint  space  may  
initially  appear  widened,  but  later  thinner  than  normal  due  to  the  loss  of  cartilage.  
(Allan 2007) However, to assess the joint space width, the radiographs should be taken 
when the animal is bearing weight on the limb which is rarely done with dogs (Marino 
& Loughin 2010; Innes 2012).  Soft tissue mineralization of the joint structures may 
also be noted on radiographs (Allan 2007). 
     Radiography has certain limitations that need to be appreciated. As the articular 
cartilage is not visible on radiographs, radiography provides information mostly on the 
bony  changes  which  might  not  be  evident  at  the  onset  of  clinical  signs  (Allan  2007;  
Innes 2012). One should also note that although radiographs are useful in diagnosing 
osteoarthritis, the radiographic findings might not correlate well with limb function 
and thus their use in the evaluation of the disease progression has been questioned 
(Gordon et al. 2003). Despite the radiographic evidence of osteoarthritis, many 
animals are asymptomatic and might not develop lameness as they age (Schulz 2007). 
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3.4.5. Synovial fluid analysis 
 
As mentioned above, synovial fluid analysis should be performed in all cases of 
suspected joint disease and it helps in distinguishing osteoarthritis from inflammatory 
arthropathies (Innes 2012). In the case of osteoarthritis the inflammatory changes on 
cytology of the synovial fluid are typically mild, but there can be gross changes such as 
the decrease in the viscosity and increase in the volume of synovial fluid (Taylor 2009; 
Innes 2012). Cellular changes attributable to osteoarthritis are summed up in Table 1. 
 
3.4.6. Others 
 
Some of the limitations of radiography can be overcome by using other imaging 
diagnostic tools. Of these arthroscopy is currently considered to be the most sensitive 
as it allows evaluation of the degree of cartilage damage and synovial proliferation in 
addition to assessment of other intra-articular structures at earlier stages than 
radiography (Schulz 2007; Innes 2012). Other imaging options in osteoarthritis that can 
also be considered are magnetic resonance imaging (MRI) and computed tomography 
(CT),  the former of  which is  generally  more useful,  as  it  provides information also on 
the soft tissue structures of the synovial joint (Innes 2012). However, as both MRI and 
CT are expensive studies to perform, they are used practically in the diagnosing of 
osteoarthritis only in human medicine. 
    The early stages of osteoarthritis are difficult to diagnose as alterations in joint 
structure and function occur before the clinical signs of osteoarthritis, which prevents 
early diagnosis and thus early initiation of treatment that could potentially help to 
delay  the  disease  process  (Matyas  et  al  2004;  Venable  et  al  2008).  There  is  also  no  
effective way to monitor the disease progression (Mobasheri & Henrotin 2010). Thus 
other diagnostic tools that might fill the areas of weakness of the other diagnostic 
procedures are being developed.  An example of this is the use of cartilage breakdown-
products as biomarkers for osteoarthritis (Garvican et al. 2010; Garvican et al. 2012).  
An ideal biomarker would bring information on the cartilage homeostasis, could be 
measured from a routine blood or urine sample before the onset of clinical signs and 
thus help in starting the treatment to prevent the development of osteoarthritis 
(Venable et al. 2008; Mobasheri & Henrotin 2010; Garvican et al. 2012). However, 
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finding such a biomarker can be challenging, mostly due to the fact that as the greatest 
proportion of cartilage in the body is found in the spine and respiratory system, the 
release  of  breakdown  products  from  a  single  diseased  joint  may  be  relatively  small  
(Garvican et al. 2010; Garvican et al. 2012). 
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MANAGEMENT OF CANINE OSTEOARTHRITIS 
 
1. OVERVIEW 
 
There is currently no known cure for osteoarthritis as there are no approved structure- 
or disease-modifying therapies that could protect the articular cartilage from further 
damage in osteoarthritis or affect the pathways of disease progression (Mobasheri & 
Henrotin 2010; Kwon & Park 2012). This, together with the fact that the diagnosis of 
osteoarthritis is often made in the late and irreversible stages, means that the 
treatment is mainly palliative as the medications only provide variable symptomatic 
relief from pain and inflammation (Johnston et al. 2008; Venable et al. 2008; 
Mobasheri & Henrotin 2010; Spakova et al. 2012). Even in human medicine there is 
currently very little that can be done for patients with mild-to-moderate osteoarthritis 
(Evans 2005). Thus there is a continuous search for better treatment options and 
studies are focused on the treatment options such as cytokine inhibitors, gene therapy 
and applications of growth factors that might have potential to preserve normal joint 
homeostasis or even reverse the structural damage in degenerative joints (Johnston et 
al. 2008; Filardo et al. 2012; Spakova et al. 2012). Such a drug capable of decreasing 
the disease progression is already available for the treatment of rheumatoid arthritis in 
humans (Chevalier & Kemta-Lepka 2010). 
    Of the treatment goals for osteoarthritis, the alleviation of pain is the most 
important (Mobasheri & Henrotin 2010). Pain management allows the patient to gain 
strength and maintain mobility (Mobasheri & Henrotin 2010; Rychel 2010). Other 
treatment goals include the maintenance of joint mobility, improvement of the 
patient’s quality of life and potentially slowing down the disease process (Kuroki et al. 
2002; Gigante & Callegari 2011). 
    The treatment of osteoarthritis is most often described as multimodal (Johnston et 
al. 2008). This means that it relies on a combination of different types of therapies 
such as administration of NSAIDs and other analgesics, nutraceuticals and functional 
foods, physical therapy and so-called alternative therapies such as acupuncture 
(Aragon et al. 2007; Sanderson et al. 2009). 
     Often the treatment decisions are affected by various different factors such as the 
practitioner’s personal experience, the compliance and goals of the owner and the 
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resources available (Johnston et al. 2008; Rychel 2010). Most canine patients are 
managed with conservative treatment options such as NSAIDs, nutritional 
supplementation, physiotherapy and weight management (Innes 2012). One should 
note that as clinical signs do not always correlate with the radiographic signs of 
osteoarthritis, it is important to tailor the treatment of osteoarthritis based on the 
patient’s symptoms instead of radiographic findings (Schulz 2007). 
 
2. TREATMENT OPTIONS 
 
2.1. Pharmacological management 
 
Based  on  the  systematic  review  of  clinical  studies  on  the  treatment  options  for  
osteoarthritis by Aragon et al. (2007), meloxicam has the strongest proof of efficacy in 
the management of canine osteoarthritis. Therapy options with a moderate proof of 
efficacy included carprofen, etodolac, pentosan polysulphate and polysulphated 
glycosaminoglycans.  
   Meloxicam along with carprofen and firocoxib was evaluated to have the strongest 
evidence of clinical effect for the treatment of osteoarthritis also in the systematic 
review by Sanderson et al (2009). Glycosaminoglycan polysulphate was evaluated to 
have moderate evidence of effectiveness while the strength of evidence for the use of 
pentosan polysulphate was evaluated to be weak.  
 
2.1.1. Analgesics 
 
2.1.1.1 Non-steroidal anti-inflammatory drugs 
 
The non-steroidal anti-inflammatory drugs are the most commonly used class of 
medication in the management of osteoarthritis (Johnston et al. 2008). This is due to 
their scientifically proven effect in the palliation of acute and chronic pain that starts 
relatively shortly after administration and last for a considerably long time (Lamont & 
Mathews 2007; Johnston et al. 2008; Innes et al. 2010a). Their relative ease of 
administration also contributes to their popularity (Johnston et al. 2008). 
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     Some practitioners prefer to use NSAIDs only as needed while others recommend 
their continuous use (Innes et al. 2010b). The continuous use of NSAIDs has been 
associated with better control of pain and better use of the joint leading to improved 
mobility (Innes et al. 2010b). Also continuous nitric oxide inhibition by NSAIDs in the 
articular cartilage might at least theoretically reduce the cell death and thus potentially 
retard the progression of osteoarthritis (Innes et al. 2010b). The amount of long-term 
studies on the adverse effects of NSAIDs is scarce (Lamont & Mathews 2007). 
However, in the systematic review by Innes et al. (2010b), the risk of serious adverse 
effects of long-term use of NSAIDs was reported to be low based on the currently 
available data. 
     Even if NSAIDs are not used on a daily basis, they are beneficial during the acute 
flares of inflammation that are common in osteoarthritis. In these cases a short course 
of NSAIDs together with the rest of 2 to 3 days may be needed.  When the phase of 
acute inflammation has subsided, normal activity level can be gradually restored. 
(Schulz 2007.) 
   Carprofen and meloxicam are examples of the NSAIDs commonly used in the 
management of canine osteoarthritis (Innes 2012). Carprofen can be given as a dose of 
4,4 mg/kg once a day or 2,2 mg/kg twice a day (Plumb 2011). In the long-term use the 
dose  is  advised  to  be  lowered  down  to  2  mg/kg  given  once  a  day  (Lääketietokeskus  
2013).  Meloxicam  is  advised  to  be  given  at  a  dose  of  0,2  mg/kg  on  the  first  day  of  
treatment and at a dose of 0,1 mg/kg once a day on subsequent days (Plumb 2011). 
   
? Mechanism of action 
 
The action of NSAIDs in mediated via the inhibition of the enzyme cyclooxygenase 
(COX) that oxidizes arachidonic acid to eicosanoids such as prostaglandins (PGs) 
(Lamont & Mathews 2007; KuKanich et al. 2012). The two main forms of COX are COX-
1 and COX-2 (Lamont & Mathews 2007; KuKanich et al. 2012). The prostaglandins 
produced by these enzymes have been shown not only to have important physiological 
functions throughout the body, but to be up-regulated upon various stimuli during 
illness (Lamont & Mathews 2007; KuKanich et al. 2012). 
     Some of the prostaglandins, such as prostaglandin E2 (PGE2), produced by COX-1 are 
vital for the mucosal defense of the gastrointestinal tract (Lamont & Mathews 2007; 
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KuKanich et al. 2012). PGE2 increases the mucus production and turnover of mucosal 
cells in the gastrointestinal tract, decreases secretion of gastric acid and increases 
bicarbonate secretion in the duodenum (KuKanich et al. 2012). Another eicosanoid 
produced by COX-1, thromboxane A2 (TXA2), is necessary for the function of platelets 
and enhances blood clot formation and coagulation (Lamont & Mathews 2007; 
KuKanich et al. 2012). Thus the inhibition of COX-1 has an anticoagulant effect 
(KuKanich 2012). 
    Also the prostaglandins produced by COX-2 have important functions in the body. 
For example, they take part in the prevention and healing of mucosal injuries, inhibit 
the adherence of leukocytes and have important physiological functions in the kidneys 
(Lamont & Mathews 2007). Especially PGE2 and prostacyclin (PGI2) are important for 
the normal function of the kidneys as they increase the excretion and inhibit the 
reabsorption of sodium and stimulate the release of renin (KuKanich et al. 2012). COX-
2 seems to have also other important physiologic functions in the body such as those 
associated with the nervous and reproductive systems and bone metabolism (Lamont 
& Mathews 2007). 
     Prostaglandins, especially PGE2 and  PGI2, are also mediators of pain and 
inflammation and thus their inhibition in osteoarthritis is desired (Lamont & Mathews 
2007). NSAIDs seem also to have central antinociceptive effects at the spinal and 
supraspinal levels (Lamont & Mathews 2007; Innes 2012). There is also evidence that 
NSAIDs might have a direct effect on cellular mechanisms of osteoarthritis at the joint 
level, potentially through the inhibition of cell death in articular cartilage induced by 
nitric oxide (Innes et al. 2010b). 
     Different NSAIDs vary in regards to which form of COX they inhibit (Lamont & 
Mathews 2007).  Some of the NSAIDs that inhibit preferentially COX-2 are meloxicam 
and carprofen while ketoprofen and aspirin are examples the NSAIDs that inhibit both 
COX-1 and COX-2 (Lamont & Mathews 2007). 
 
  • Potential side effects and contraindications 
 
The main adverse effects of NSAIDs are associated with the gastrointestinal tract, the 
kidneys  and  the  impairment  of  platelet  activity  (Innes  2012).  As  dogs  are  more  
susceptible  to  the  side  effects  of  NSAIDs  than  people  and  most  of  the  drugs  in  this  
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class  have  narrow  safe  margins,  accurate  dosing  is  vital  (Lamont  &  Mathews  2007).  
Due to individual variations in response to different NSAIDs, switching NSAIDs to 
determine which one is the most effective for the patient may be advisable, especially 
if controlling pain requires high doses of a particular NSAID (Lamont & Mathews 2007; 
Taylor  2009).  In  these  cases  a  washout  period  of  minimum  of  3  days  should  be  left  
before  starting  the  new  drug  to  reduce  the  risk  of  adverse  effect  (Taylor  2009).  
Concurrent use of NSAIDs with glucocorticoids should also be avoided as it has been 
linked with increased risk of side effects, especially gastrointestinal ulceration 
(KuKanich et al. 2012). 
     Most of the adverse effects caused by NSAIDs are considered to be associated with 
the gastrointestinal tract (KuKanich et al. 2012). As weak acids NSAIDs can cause direct 
irritation of the mucosa after oral administration or following secretion in bile after 
hepatic elimination (KuKanich et al. 2012). However, the adverse effects are also 
mediated  indirectly  through  the  inhibition  of  PGE2 and  PGI2 since these eicosanoids 
help to protect the gastrointestinal mucosa from injury as stated earlier (Innes et al. 
2010a; KuKanich et al. 2012). Other potential mechanisms by which NSAIDs may exert 
adverse effects on the gastrointestinal tract are increased production of leukotrienes 
and inhibition of aspirin triggered lipoxin (KuKanich et al. 2012). Thus NSAIDs should be 
avoided or at least used cautiously in patients with gastrointestinal damage due to 
ulceration or intestinal surgery (KuKanich et al. 2012). 
      Other contraindications of NSAIDs are acute renal failure, dehydration and 
coagulopathies (Lamont & Mathews 2007). Due to the inhibition of PG activity, NSAIDs 
may also be harmful for reproductive function and should not be used during 
pregnancy (Lamont & Mathews 2007). Since most NSAIDs are eliminated by the liver, 
hepatic  disease  might  be  a  relative  contraindication  for  the  use  of  NSAIDs,  as  it  can  
lead to increased drug exposure and thus increase the risk of adverse effects (KuKanich 
et al. 2012). Using NSAIDs in animals with disorders causing impaired visceral perfusion 
such as heart failure can increase the risk of gastrointestinal ulceration (Taylor 2009). A 
thorough physical examination and collecting minimum database including complete 
blood count, serum biochemistry and urinalysis should be performed prior to starting a 
NSAID therapy to help to rule out possible contraindications for NSAID use (Rychel 
2010). 
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   The symptoms to be monitored during NSAID therapy include hematochezia or 
melena, vomiting, increased water consumption and nonspecific changes in demeanor 
(Lamont & Mathews 2007). In the long-term use creatinine and alanine 
aminotransferase monitoring is recommended (Lamont & Mathews 2007). 
     Clinical signs that may be caused by gastric ulceration include depression, reduced 
appetite, vomiting, diarrhea and digested blood in the vomitus or feces, although some 
dogs with gastric ulceration don’t show any obvious symptoms (KuKanich et al. 2012). 
If such signs occur during the therapy, the administration of NSAIDs should be 
discontinued until the signs subside (KuKanich et al 2012). After the clinical signs have 
resolved, several approaches can be taken, although their safety or efficacy has not 
been evaluated (KuKanich et al. 2012). The administration of NSAIDs can be continued 
with a concurrent administration of a gastroprotectant such as omeprazole, famotide 
or misoprostol (KuKanich et al. 2012). Other options are reducing the drug dose by 
adding an analgesic drug of another class or switching to another type of analgesic or 
to a different NSAID (Lamont & Mathews 2007; KuKanich et al. 2012). 
 
2.1.1.2. Other analgesic drugs 
 
Combining other analgesic drugs with NSAIDs has certain benefits in treating chronic 
pain (Lamont & Mathews 2007). Not only can they help to control pain refractory to 
NSAIDs, but they may also enable the dose reduction of NSAIDs thus reducing the risk 
of NSAID-induced side effects (Lamont & Mathews 2007). They might also be of 
benefit for animals with significant liver, renal or gastrointestinal disease or for 
patients that do not tolerate NSAID administration (Rychel 2010). Examples of the 
analgesic adjuvants that can be used in the management of osteoarthritis include 
tramadol, amantadine, gabapentine and amitriptyline (Lamont & Mathews 2007; 
Plumb 2011; KuKanich et al. 2012). Although the aforementioned analgesic drugs are 
in clinical use, the scientific evidence on their efficacy in the treatment of canine 
osteoarthritic pain is scarce. Only the efficacy of amantadine has been investigated in a 
controlled clinical trial in osteoarthritic dogs (Johnston et al. 2008). 
     Tramadol is an opiate-like agonist with µ-receptor activity (Plumb 2011). It also 
inhibits the reuptake of serotonin and norepinephrine (Rychel 2010; Plumb 2011). It is 
commonly administered for veterinary patients combined with a NSAID (Johnston et 
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al. 2008). For mild chronic pain in dogs it is commonly administered per orally at doses 
of 2-5 mg/kg 2-3 times a day together with another type of analgesic such as a NSAID 
(Plumb 2011). However, dosage adjustments might be needed in patients with hepatic 
or renal disease (Plumb 2011). Tramadol is generally well tolerated in dogs (Plumb 
2011). Possible side effects include sedation, anxiety and problems associated to the 
gastrointestinal tract such as vomiting, constipation and diarrhea (Plumb 2011). 
     Amantadine inhibits the N-methyl-?-aspartate (NMDA) receptors that are found in 
the dorsal spinal horn and whose activation is associated with chronic pain (Johnston 
et al. 2008; Rychel 2010). In the management of osteoarthritis, amantadine is not likely 
to be effective when administered as the only analgesic, but together with a NSAID it 
might  be  beneficial  (Johnston  et  al.  2008;  Plumb  2011).  In  a  study  by  Lascelles  et  al.  
(2008) on the effect of amantadine used in combination with meloxicam was found 
beneficial in alleviating pain in osteoarthritic dogs. No side-effects were reported. 
Amantadine can be used to manage pain caused by osteoarthritis at doses of 3-5 
mg/kg given perorally once a day (Plumb 2011). However, as amantadine is eliminated 
via the kidneys, dosage adjustments might be needed when it is used in dogs with 
renal disease (Plumb 2011). 
     Gabapentin has been found to be beneficial in the treatment of neurogenic pain 
although the mechanism by which gabapentin exerts its analgesic action is not 
completely understood (Johnston et al. 2008; Plumb 2011). However, it is thought to 
decrease the release of excitatory neurotransmitters by binding to the voltage-gated 
calcium channels (Plumb 2011). In the management of osteoarthritis the doses of 5-10 
mg/kg  twice  daily  with  or  without  together  a  NSAID  can  be  used  (Plumb  2011).    As  
gabapentin is eliminated via the kidneys, dose adjustments might be needed in dogs 
with severe renal dysfunction (Plumb 2011). 
     The most common side effect of gabapentin is sedation. Thus it is recommended to 
be started with a lower dose. Sudden discontinuation of gabapentin should also be 
avoided, because it has been associated with potential withdrawal-precipitated 
seizures. (Plumb 2011.) 
    Amitriptyline is primarily used to treat behavioral conditions such as anxiety, but it 
has also potential in the management of neuropathic pain (Johnston et al. 2008; Plumb 
2011). Amitriptyline is a tricyclic antidepressant drug that causes the blockage of the 
amine pump leading to increased neurotransmitter levels, sedation and 
21 
 
anticholienergic  activity  (Plumb  2011).  It  also  is  binds  to  the  H1 receptors, sodium 
channels and glutamate receptors (Plumb 2011). Doses of 1-2 mg/kg once or twice a 
day can be used in the management of canine osteoarthritis (Plumb 2011). As 
amitriptyline is metabolized in the liver, it should be used cautiously in patients with 
hepatic disease (Plumb 2011). The most common side effects are sedation and 
anticholinergic effects such as constipation and urinary retention (Plumb 2011).  
 
2.1.2. Other pharmacological treatment options 
 
Other pharmacological treatment options include polysulfated glycosaminoglycan and 
pentosan polysulfate (Innes 2012). Although they are used intra-articularly in the 
equine practice, there are currently no reports on their use in dogs (McIlwraith 2011). 
Polysulfated glycosaminoglycan and pentosan polysufate might have structure-
modifying effects in the treatment of osteoarthritis, although this is yet to be proven 
(Innes 2012).  
      Pentosan polysulfate is a semisynthetic glycosaminoglycan that can be used in the 
management of canine osteoarthritis for its potential chondroprotective functions 
(Plumb 2011; Innes 2012). In Finland pentosan polysulfate is available only as an 
injectable solution (Carthrophen® 100 mg/ml) that is administered subcutaneously as a 
dose of 3 mg/kg as four injections with 5-7 days apart (Plumb 2011; Lääketietokeskus 
2013).  
   In a review by Hannon et al. (2003) of the reported side effects of pentosan 
polysulphate product Carthrophen Vet® in the UK the most commonly reported 
adverse effects were general changes in the dog’s demeanour, such as inappetance 
and lethargy, and vomiting. It should also be noted that as pentosan poysulfate has 
potential anticoagulant effects, its concurrent use with a NSAID is not recommended 
(Plumb 2011). 
     The exact mechanism of action of polysulfated glycosaminoglycan (PSGAG) is not 
known, although it has been licensed for the treatment of canine osteoarthritis in 
some countries (Innes 2012). There is currently no licensed injectable drug formulation 
of polysulfated glycosaminoglycan for dogs in Finland. The proof of efficacy of PSGAG 
has  also  been  evaluated  to  be  only  weak  to  moderate  in  two  systematic  reviews  
(Aragon et al. 2007; Sanderson et al. 2009).  Polysulphated glycosaminoglycan can be 
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given as a dose of 4,4 mg/kg intramuscularly twice a week for up to 4 weeks (Plumb 
2011). As PSGAG is a heparin analogue, its use in patients with a bleeding disorder and 
concurrent use with a NSAID should be avoided (Johnston et al. 2008). 
 
2.2. Non-pharmacological management 
 
2.2.1. Weight management 
 
As discussed previously, obesity is a potential predisposing factor for the development 
of  osteoarthritis  both  by  increasing  the  risk  of  mechanical  injury  to  the  articular  
structures and by creating a state of chronic systemic inflammation (Rychel 2010; 
Innes 2012). Obesity may also be the result of long-term chronic pain that has led to 
the reluctance to exercise (Schulz 2007).  Overweight pets with osteoarthritis are also 
more likely to be inactive, as extra weight increases the load on sore joints, and gain 
even  more  weight  which  initiates  a  vicious  cycle  (Rychel  2010).  Since  in  addition  to  
osteoarthritis, a higher incidence of other diseases such as diabetes mellitus, hepatic 
lipidosis, cardiovascular and respiratory problems and dermatitis has been linked to 
obesity, weight loss is advisable (Nelson et al. 2007).  
    Most common reasons for obesity are excessive caloric intake and reduced daily 
activity, although a genetic predisposition has been identified in certain breeds such as 
the Labrador Retriever and Cocker Spaniel. Obesity is less frequently caused by an 
endocrine disease such as hypothyroidism, hyperadrenocorticism or hyperinsulinism 
or drugs such as progestagens or corticosteroids. (Taylor 2009.) 
    There are studies that suggest that weight loss alone can ameliorate the clinical signs 
and improve mobility in obese dogs with osteoarthritis (Johnston et al. 2008). One of 
these studies was performed by Marshall et al (2010) on the effect of weight loss on 
lameness in fourteen obese dogs with osteoarthritis. An average of 8,6 % reduction of 
the initial body weight during the 16-week-long study period resulted in improvement 
in lameness assessed both visually and by kinetic analysis.  
    The rate of weight loss should be 1 to 2 % per week at maximum as a faster rate is 
more likely to lead to reduced patient and client compliance and loss of muscle mass 
instead of fat (Taylor 2009). This is usually achieved by reducing the caloric intake to 80 
% and then adjusting the diet based on regular weigh-ins (Taylor 2009). Regular 
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veterinary check-ups are an important part of the weight loss program (Schulz 2007; 
Taylor 2009).  
 
2.2.2. Physical rehabilitation and exercise adjustments  
 
Physical rehabilitation in the management of osteoarthritis includes the use of 
exercise,  massage,  heat,  cold,  water,  sound  and  electricity  to  improve  function  and  
reduce pain (Dunning & Lascelles 2007; Johnston et al. 2008; Rychel 2010). Increased 
circulation and lymph flow in the affected area, the prevention of muscle atrophy and 
reduction of inflammation are examples of the potential beneficial effects of physical 
rehabilitation (Johnston et al. 2008). 
      Local  hypothermia,  also  known  as  cryotherapy,  means  the  application  of  
therapeutic cold on musculoskeletal tissues. It is most useful in acute cases of 
inflammation,  such  as  less  than  72  hours  after  an  injury  or  during  the  acute  
exacerbations  of  osteoarthritis  (Dunning  &  Lascelles  2007;  Rychel  2010).  Local  
hypothermia minimizes edema through vasoconstriction, decreases enzyme activity 
and metabolism in tissues and provides analgesia by affecting the nerve conduction of 
the  sensory  nerves  and  by  causing  relaxation  of  the  skeletal  muscle  (Dunning  &  
Lascelles 2007). Cryotherapy should be used for 5 to 15 minutes at a time up to four 
times a day (Dunning & Lascelles 2007; Rychel 2010). 
  Local hyperthermia, or heat therapy, is recommended to be used once the phase of 
acute inflammation has subsided, which usually means 24 to 72 hours after injury or 
surgery (Dunning & Lascelles 2007). The benefits of heat therapy are similar to those of 
cryotherapy as it reliefs pain and provides muscle relaxation (Dunning & Lascelles 
2007). Local hyperthermia can also increase the extensibility of articular or 
ligamentous collagen (Dunning & Lascelles 2007). The recommended duration of 
application is 15 to 20 minutes two to four times daily (Dunning & Lascelles 2007; 
Rychel 2010). 
     Passive range of motion exercises, that help to maintain the normal range of motion 
of joints, and therapeutic exercises such as walking on inclines, that help to strengthen 
the muscles that support the diseased joint and improve coordination in a controlled 
manner, may also be useful in the management of osteoarthritis (Dunning & Lascelles 
2007; Schulz 2007).  
24 
 
   Although there are currently only a few studies on the effect of exercise 
modifications on canine osteoarthritis, keeping the dog fit with regular and controlled 
exercise of moderate intensity is recommended as this helps to maintain the joint 
range of motion and muscle strength (Schulz 2007; Innes 2012). Swimming, for 
example,  is  an  effective  form  of  exercise  for  dogs  with  osteoarthritis  (Taylor  2009).  
During the acute flares of osteoarthritis, a rest of a few days is recommended before 
the gradual return to exercise (Schulz 2007). 
 
2.2.3. Nutritional supplementation 
 
Nutritional supplements can be given to the animal as nutraceuticals and functional 
foods (Innes 2012).    The term nutraceutical is used to describe a food or a part of a 
food that has medical or health benefits including the prevention and treatment of 
disease (Innes 2012; Vandeweerd et al. 2012). Functional foods are whole foods in 
which these supplements have been added (Innes 2012). 
     Glucosamine and chondroitin sulfate are among the most commonly used 
nutraceuticals  although  the  evidence  for  their  use  varies  (Rychel  2010;  Innes  2012).   
Studies on the distribution of orally administered labeled chondroitin sulfate indicate 
that this nutraceutical might not reach the articular cartilage at all or at least not intact 
(Innes 2012). Thus based on the current evidence the use of chondroitin sulfate cannot 
be recommended for the management of canine osteoarthritis (Innes 2012). Slightly 
stronger evidence exists for the use of glucosamine in the management of 
osteoarthritis as it has been shown to increase proteoglycan synthesis in vitro and to 
have a weak anti-inflammatory effect in animal models (Innes 2012). However, clinical 
studies on using glucosamine alone in animals are needed before specific 
recommendations on its use can be given (Innes 2012). However, as neither of these 
nutraceuticals is associated with severe side-effects or absolute contraindications, 
their use is generally considered to be safe (Plumb 2011). 
     Other examples of nutraceuticals are essential fatty acids such as omega-3 fatty 
acid, avocado soybean unsaponifiable products, green-lipped mussel preparations, 
resin extract of the tree Boswellia serrata and vitamin C (Johnston et al. 2008; Rychel 
2010; Innes 2012).   
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     The problem with nutraceuticals is the lack of high quality studies on their efficacy 
in osteoarthritis (Vandeweerd et al. 2012). The systematic search of controlled clinical 
studies on the effect of nutraceuticals in horses, dogs and cats by Vandeweerd et al 
(2012) revealed only 25 studies that met the inclusion criteria. Five of these studies 
were performed in horses, sixteen in dogs and one in cats. According to this systematic 
review, omega-3 fatty acids were found to have the highest evidence of efficacy in the 
alleviation of clinical signs of osteoarthritis. For other reviewed nutraceuticals, such as 
hydroxycitric  acid,  P54FP,  gelatine  hydrosylate,  ?-1,3/1,6  glucans  and  special  milk  
protein concentrate, the strength of evidence was evaluated to be low.  
 
2.2.4. Other non-pharmacological treatment options 
 
One of the alternative therapy options for pain management is acupuncture. It is being 
more commonly used in the pain management of  veterinary patients  (Henrotin et  al.  
2005; Skarda & Glowaski 2007). The exact mechanisms of action of medical 
acupuncture are not known, but the release of endogenous endorphins, local release 
of muscle spasm and decreased pain transmission to the spinal cord are likely to be 
involved (Rychel 2010). Although acupuncture seems to have potential as a treatment 
adjuvant, based on the current knowledge it should not replace the so-called Western 
treatments (Skarda & Glowaski 2007). 
     Examples of other alternative treatment options are homeopathy, chiropractic 
therapy  and  the  use  of  herbal  and  plant  medicines  (Henrotin  et  al.  2005).  However,  
inclusion of these therapy options to the treatment plan should be done cautiously as 
scientific evidence of their effects is scarce (Henrotin et al. 2005; Skarda & Glowaski 
2007). 
 
2.3. Surgical management 
 
Pain that cannot be controlled by other means and the loss of limb function are 
indications  for  surgical  management  of  osteoarthritis.  Surgical  treatment  is  a  salvage  
procedure that is chosen in cases where other therapy options have failed (Aragon et 
al. 2007; Schulz 2007.) 
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     Arthroplasty techniques, such as removal of femoral head and neck, joint 
replacement with prosthesis, surgical fusion of the joint with arthrodesis techniques or 
even amputation may be considered in patients whose symptoms do not respond to 
non-surgical treatment options (Schulz 2007).  
     Surgical management is also often indicated in treating the underlying orthopedic 
condition, such as cranial cruciate ligament rupture, if one can be identified (Schulz 
2007). 
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INTRA-ARTICULAR INJECTIONS IN THE MANAGEMENT OF CANINE OSTEOARTHRITIS 
IN COMPARISON TO THEIR USE IN HORSES AND HUMANS 
 
Intra-articular injections are less routinely used in the management of canine 
osteoarthritis compared to their use in horses and humans. The amount of scientific 
publications on their effects in dogs is also very scarce. Thus studies on the effects of 
intra-articular medications also on horses and humans are included in the review. 
 
1. GENERAL PRINCIPLES OF INTRA-ARTICULAR INJECTIONS 
1.1. Clinical use 
 
? In veterinary medicine 
 
Local intra-articular therapy is considered to be well suited to the management of 
osteoarthritis that is symptomatic only in a limited number of weight-bearing joints 
and  lacks  obvious  systemic  manifestations  (Evans  2005;  Larsen  et  al.  2008;  Singh  
2012).  
    In veterinary medicine intra-articular injections as a part of the management of 
osteoarthritis are mainly used in horses, in which species they play a significant role in 
the management of joint-related lameness (Caron 2005; Edwards 2011). Some of the 
reasons  for  this  are  the  high  prevalence  of  joint  diseases  in  horses  and  the  need  to  
develop an alternative for NSAID therapy, that despite being an inexpensive and 
generally effective treatment option for reducing lameness in horses with 
osteoarthritis, is usually strictly regulated or even forbidden in competing horses and 
associated with potential side-effects (Caron 2005; Lamont & Mathews 2007; Edwards 
2011). The pain-relieving effect of other systemic treatment options, such as 
nutraceuticals, is not comparable to that of the NSAIDs (Caron 2005). Another reason 
for the more frequent use of intra-articular injections in horses compared to the other 
veterinary species is that the lower limb joints of the horse are relatively easy to inject 
(Edwards 2011). Corticosteroids are the mainstay of intra-articular therapy in horses 
(McIlwraith 2011). The two other commonly used intra-articular agents are hyaluronic 
acid and polysulfated glycosaminoglycan (Edwards 2011).  
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     Despite the wide-spread clinical use of intra-articular medications in the equine 
practice, the scientific basis for their use is not completely established (Clegg 2010). A 
problem with the current studies, in addition to their limited number, is that they have 
been mostly performed either in vitro or in animal models of osteoarthritis (Clegg 
2010; McIlwraith 2011). The results from these studies might not be fully translatable 
into the treatment of naturally occurring disease (Clegg 2010). 
     The lack of high quality clinical studies on the effects of intra-articular medications 
in the management of osteoarthritis is a problem also in the canine practice, although 
the effects of certain intra-articular agents, such as corticosteroids and hyaluronic acid, 
have been studied in the canine joint (Pelletier & Martel-Pelletier 1989; Pelletier et al. 
1994; Smith 2005b). Compared to their use in horses, intra-articular medications are 
considerably less routinely used in the canine practice. Some of the reasons behind 
this might be that their efficacy in the management of osteoarthritis is not fully 
established in any species and because arthrocentesis in dogs usually requires 
sedation.  
 
? In human medicine 
 
In human medicine the intra-articular injections are mainly used in the symptomatic 
treatment of knee osteoarthritis and they are considered as an additional treatment 
option in cases where other conservative treatment options have not been adequate 
in relieving the symptoms (Waddell 2007; Hameed & Ihm 2012; Keith 2012). Like in 
horses, corticosteroids and hyaluronic acid are the most commonly used intra-articular 
agents also in humans (Edwards 2011; Keith 2012).  
     As  there  are  only  few  studies  comparing  the  effects  of  hyaluronic  acid  directly  to  
those of the corticosteroids, there are currently no definite recommendations 
regarding which of these two should be used as the initial injection (Keith 2012). Often 
intra-articular steroids are considered as the mainstay of injection therapy and 
hyaluronic acid as the second-line option (Zhang et al. 2008). Some authors suggest 
that corticosteroids might be more beneficial than hyaluronic acid in cases where the 
patient has an acutely inflamed osteoarthritic joint while hyaluronic acid might be 
more beneficial when the patient’s condition is rather stable and the pain caused by 
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osteoarthritis is mild to moderate (Bannuru et al. 2009; Ara & Alam 2011; Hameed & 
Ihm 2012). 
      
1.2. Advantages and disadvantages of using intra-articular drug delivery  
 
? Advantages of the intra-articular drug therapy  
 
 The articular cartilage is avascular and alymphatic and as such is difficult to reach by 
using the systemic drug administration (Chevalier & Kemta-Lepka 2010; Kwon & Park 
2012). Drugs from blood circulation reach the cartilage only by passive diffusion from 
the synovial fluid (Gege et al. 2012). Human studies suggest that the peak 
concentration of a drug after the oral administration is usually lower and is reached 
later  in  the  synovial  fluid  than  in  plasma  (Larsen  et  al.  2008).  On  the  other  hand,  
studies have also shown that after the steady state conditions have been achieved, the 
free NSAID concentrations are similar in synovial fluid and plasma (Larsen et al. 2008). 
The NSAID concentrations have also been shown to be more sustained in the synovial 
fluid than in plasma after oral or intravenous administration (Larsen et al. 2008) 
     To achieve a sustained therapeutic intra-articular drug concentration, high doses of 
a systemically given drug are often needed (Gege et al. 2012). This is not desired at all, 
as some of the currently available systemic treatment options are commonly 
associated with gastrointestinal, hepatic, renal and cardiac adverse effects, especially 
in  older  animals  and  people  (Lamont  &  Mathews  2007;  Singh  2012).  One  of  the  
advantages of the use of intra-articular drug administration in joint diseases is the 
opportunity to deliver the drug directly to the cartilage while minimizing systemic 
exposure (Larsen et al. 2008; Edwards 2011; Kwon & Park 2012). Thus a smaller 
amount of drug is required for the desired pharmacological effect (Larsen et al. 2008). 
For certain drug candidates the local administration might even be the only realistic 
route of administration due to the severe systemic side effects with oral 
administration, low bioavailability or extensive degradation in vivo (Larsen et al. 2008; 
Chevalier & Kemta-Lepka 2010). 
    It is still unlikely, that local therapy would completely replace systemic therapies, 
even if an ideal medication was identified, since in some cases osteoarthritis is a 
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systemic disease with multiple joint involvement. Thus the need for better systemic 
treatment options still exists. (Singh 2012.)  
 
? Challenges associated with intra-articular injections 
 
The synovial cavity is not isolated but it is in direct equilibrium with circulation. The 
wide intercellular spaces and superficial capillaries in the synovium allow free flow of 
water and solutes so that the fluid volume in a joint cavity is replaced multiple times in 
a day. Thus the major reason for treatment failure following intra-articular drug 
administration is the rapid clearance of the drug from the joint space. (Edwards 2011.) 
     Small molecules, such as the cytokines and most drugs including the corticosteroids, 
NSAIDs and local anesthetics, diffuse through the synovial lining with ease (Edwards 
2011). Thus for many drugs the absorption and redistribution into the systemic 
circulation following an intra-articular injection are actually comparable to other non-
intravenous parenteral routes (Edwards 2011).  Often this clearance from the synovial 
cavity  is  further  accelerated  by  synovitis  (Kwon  &  Park  2012).  Thus,  the  biggest  
challenges in using intra-articular drug delivery are keeping the drug concentration 
stable in the joint cavity and preventing the drug from leaving the joint space and 
distributing throughout the body (Edwards 2011; Kwon & Park 2012). 
     The desired drug concentration could be maintained over extended periods of time 
by repeated intra-articular administrations, but repeated intra-articular injections are 
neither feasible nor safe due to the increased risk of infection (Evans 2005; Larsen et 
al.  2008).  In  addition  to  this,  since  dogs  are  recommended  to  be  sedated  or  
anesthetized for intra-articular injections, in canine practice repeated intra-articular 
injections would also mean repeated sedations. More ideally the stable drug 
concentration in the synovial cavity would be achieved by immobilizing the active 
agent into an injectable depot formulation from which it would be released in a 
controlled manner (Larsen et al. 2008). For this reason current studies revolve around 
creating sustained-release drug formulations (Edwards 2011; Kwon & Park 2012). 
      The accurate needle placement obviously affects the efficacy and safety of intra-
articular medications and may be particularly problematic in conscious patients 
(Edwards 2011; Smart 2012). This is not a problem only in veterinary medicine but also 
in human medicine since while rheumatologists may achieve full accuracy, it has been 
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estimated that in hospital settings almost one-third of the knee injections may actually 
not even reach the joint cavity (Edwards 2011). This happens despite the fact that the 
joint cavity of human knee joint is relatively large and accessible compared to that of 
the stifle joint of many of the dog breeds (Edwards 2011).   
     In humans the accuracy of needle placement has been recommended to be 
confirmed by the return of synovial fluid during the joint aspiration (Smart 2012). 
Inspecting the gross appearance of synovial fluid before injecting the drug is also 
advisable, as purulent effusion on aspiration is clearly a contraindication for intra-
articular medications (Philipose et al. 2011). 
     The amount of synovial fluid in chronically affected joints might be so reduced that 
no synovial fluid can be aspirated before the injection, which makes it difficult to be 
assured  that  the  needle  is  accurately  placed  in  the  synovial  cavity  (Smart  2012).  In  
these cases the accuracy of the injection can also be improved by using imaging such 
as ultrasonography as an aid, as is often done in human medicine when injecting the 
joints of hands (Edwards 2011; Iannitti et al. 2011). In dogs arthrography has also been 
used to confirm the correct needle placement (Hadley et al. 2010). 
   Achieving a correct diagnosis of an intra-articular disease is also important, as an 
intra-articular  medication  lacks  efficacy  also  in  cases  where  the  pain  actually  stems  
from the soft tissues surrounding the joint (Edwards 2011). 
 
? Potential risks associated with intra-articular injections 
 
The use of intra-articular medications is not completely free from potential adverse 
effects. In humans some of the reported complications associated with intra-articular 
injections are infection, post-injection flare, crystal-induced synovitis, cutaneous 
atrophy  and  steroid  arthropathy  (Iannitti  et  al.  2011;  Kwon  &  Park  2012).  Although  
these side effects are rare, introducing bacteria into the joint cavity is a major concern, 
because the consequences of septic arthritis can be devastating (Edwards 2011; 
Iannitti et al. 2011; Kwon & Park 2012). The risk of septic arthritis is considered to be 
especially high when using intra-articular corticosteroids that have the potential to 
suppress the inflammatory response to microbes (Singer 2008; Edwards 2011). 
     The prevalence of septic arthritis following intra-articular injections in dogs has not 
been investigated, but the overall incidence of septic arthritis, whether arising from 
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the penetration of the joint capsule due to surgery or trauma, hematogenous spread 
or  spread  from  adjacent  tissues,  is  low  in  the  canine  practice  (Ridge  2011).  The  
incidence of septic arthritis following elective arthroscopic surgery was reported to be 
0,85 % in 294 dogs and 11 cats in the retrospective study by Ridge (2011). The 
incidence of septic arthritis is low also in humans, as the prevalence of joint infection 
associated with intra-articular corticosteroid injections has been reported to be around 
4 cases in every 10 000 injections (Mathews 2010). The risk of septic arthritis can be 
reduced by using strict aseptic technique as described below and by abstaining from 
injecting  intra-articular  medications  in  cases  where  there  are  signs  of  a  systemic  or  
local infection (Caron 2005; Hameed & Ihm 2012). 
     In some cases the drug itself can be the cause of the inflammatory response, 
because the synovium is highly reactive (Edwards 2011). For example, in some horses, 
saline and hyaluronic acid injections as such have been shown to evoke a marked 
inflammatory response and to cause lameness (Edwards 2011). It is often challenging 
to differentiate reactive arthritis from septic arthritis, because of the similarities in the 
clinical signs and even in the findings on cytology of synovial fluid (Singer 2008). As the 
consequences of septic arthritis can be severe, it is often safer to start the treatment 
as if the cause of inflammation is infectious whenever acute lameness follows an intra-
articular injection (Singer 2008). 
 
1.3. Injection technique 
 
The injection site should be aseptically prepared, which includes the clipping off the 
hair and the surgical scrubbing and disinfecting of the skin (Fossum 2007; Taylor 2009) 
Sterile gloves and single-use syringes and needles should be used to reduce the risk of 
introducing bacteria into the joint (Caron 2005). Recommended sites for arthrocentesis 
in dogs are shown in Figure 2.  
   The literature recommends the use of 25-gauge needles for arthrocentesis in small 
dogs and 22-gauge needles for arthrocentesis in larger dogs (Taylor 2009). However, it 
can be difficult to aspirate synovial fluid through a small needle as it is very viscous. 
Therefore, 21-gauge needles are commonly used for arthrocentesis in large dogs and 
23-gauge needles for arthrocentesis in small dogs and cats (Helka Heikkilä, personal 
communication). Because of the thick musculature, reaching the hip joint of large dogs 
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might even require using a 3-inch spinal needle (Taylor 2009). The needle should be 
attached  to  the  syringe  before  it  is  inserted  into  the  joint  and  as  stated  above,  the  
correct needle placement should be verified before injecting the medication (Clements 
2006). In human medicine, some practitioners remove the excessive effusion fluid 
before the injection, as this not only helps to reduce the concentration of 
inflammatory mediators in the joint cavity, but also makes sure that the injected 
medication will not be excessively diluted (Strauss et al. 2009). Removing the excessive 
synovial fluid might also relieve pain that is caused by the stretching of the joint 
capsule (Liebich et al. 2007). After the injection any negative pressure on the syringe is 
released before the withdrawal of the needle (Taylor 2009). 
 
 
    
Figure 1. Recommended sites of arthrocentesis in dogs (Fossum 2007). 
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2. OVERVIEW OF THE MEDICATIONS FOR INTRA-ARTICULAR THERAPY OF 
OSTEOARTHRITIS 
The following list of medications used or studied in the intra-articular treatment of 
osteoarthritis is not exhaustive. The focus of the review is on corticosteroids and 
hyaluronic acid, because they are the most commonly used intra-articular medications 
in both human and veterinary medicine.  Some of the new therapy options with 
potential clinical use in the near future will also be discussed. 
 
2.1. CORTICOSTEROIDS 
 
2.1.1. Mechanism of action 
Despite their popularity, the exact mechanism by which corticosteroids affect the 
osteoarthritic joint is not completely known, but their effect is thought to be mostly 
mediated through the inhibition of the activity of phospholipase A leading to reduced 
production of both cyclooxygenases and lipoxygenases (Schulz 2007; Gege et al. 2012). 
Intra-articular steroids reduce the number of inflammatory cells such as lymphocytes, 
macrophages and mast cells which in turn decreases phagocytosis, lysosomal enzyme 
release and the release of inflammatory mediators (Lavelle et al. 2007). Corticosteroids 
also inhibit a number of cytokines and enzymes involved in the articular cartilage 
degeneration in osteoarthritic joints (Caron 2005; Lavelle et al. 2007). They have been 
shown to reduce the release of leukotrienes and prostaglandins and  the expression of 
two of the most important mediators of cartilage degradation, interleukin-1 (IL-1) and 
tumor necrosis factor-? (TNF-?) (Caron 2005; Lavelle et al. 2007). Corticosteroids 
might also protect the cartilage by reducing metalloproteinase activity (Schulz 2007). 
 
2.1.2. Scientific evidence and clinical use 
 
? In veterinary medicine  
 
The use of corticosteroids has a long history in veterinary medicine since the report on 
the use of hydrocortisone in the treatment of different musculoskeletal conditions in 
horses and cattle was released by Wheat et al. already in 1955 (McIlwraith 2010). 
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Despite this, almost all of the studies on the effects of corticosteroids in the 
management of canine or equine osteoarthritis have been performed in vitro or on 
animal models. 
      The results from these studies have also been rather contradictory (Hossain et al. 
2008; Innes 2012). On the one hand some protective function of intra-articular 
corticosteroids on articular cartilage has been demonstrated in experimental canine 
models, but on the other hand undesired effects, such as increased apoptosis and 
suppressed proliferation of chondrocytes, have also been demonstrated in in vitro 
studies (Pelletier et al. 1994; Hossain et al. 2008). 
     The only controlled prospective studies currently available on the effects of intra-
articular corticosteroid injections on osteoarthritis in dogs date back to the late 1980s 
and early 1990s (Pelletier et al. 1989; Pelletier & Martel-Pelletier 1991; Pelletier et al 
1994; Pelletier et al. 1995). However, these studies investigate the effect of 
corticosteroids on the histological and macroscopic severity of osteoarthritis rather 
than on the clinical signs.  
         The effect of intra-articular triamcinolone hexacetonide was studied by Pelletier 
et al. (1989). In this study osteoarthritis was induced for twenty-four dogs by the 
severance of the cranial cruciate ligament. The treatment group consisted of twelve 
dogs of which six dogs received oral prednisolone and six dogs received 5 mg of 
triamcinolone hexacetonide intra-articularly at the time of the induction of 
osteoarthritis and four weeks later. The control group consisted of twelve dogs that 
received no treatment. The macroscopic changes, such as osteophyte formation and 
changes in the gross appearance of articular cartilage, as well as the histological 
changes attributable to osteoarthritis were shown to be less severe in the treatment 
group compared to those in the control group. Also, no evidence of increased cell 
degeneration or cell death caused by corticosteroids was noted. 
    In another study by Pelletier et al. (1994) osteoarthritis was induced for fifteen dogs 
also by severing the cranial cruciate ligament. The treatment group consisted of eight 
dogs that received an intra-articular injection of 20 mg of methylprednisolone acetate 
into the stifle joint at the time of the induction of osteoarthritis and four weeks later. 
The control group consisted of seven dogs that did not receive any treatment. The 
results showed that the osteophyte formation and the histologic signs of osteoarthritis 
in the articular cartilage, such as fibrillation and fissure formation of the cartilage 
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surface, were significantly less severe in the dogs of the treatment group compared to 
those in the control group. 
     In  a  small  patient  series  by  Kinzel  et  al.  (2003)  intra-articular  triamcinolone  
acetonide (10 mg/joint) was used with lidocaine in the treatment of osteoarthritic pain 
in the cervical facet joints of client-owned Scottish Deerhounds. Eight out of nine dogs 
responded to the treatment and seven of the dogs were painless for more than four 
months. Although the results of this study were interesting, they should be interpreted 
with care since this was a retrospective study with no control group and possibly with 
some selection bias in the inclusion criteria. 
      Intra-articular corticosteroids are commonly used in the treatment of equine 
osteoarthritis, although the scientific evidence on their efficacy in equine osteoarthritis 
is  scarce  (McIlwraith  2011).  Most  of  the  current  studies  in  horses  are  either  in vitro 
studies or performed on animal models of osteoarthritis (McIlwraith 2010).  
  An example of a study on horses with naturally occurring osteoarthritis is the 
retrospective  study  by  Labens  et  al.  (2007).  Forty-eight  horses  with  osteoarthritis  in  
the distal tarsal joints were treated with methylprednisolone acetate or triamcinolone 
acetonide, either alone or combined with hyaluronic acid. Although the grade of 
lameness improved in approximately sixty percent of the treated limbs, about ninety 
percent  of  the  horses  were  lame  again  at  the  second  control  visit  that  was  done  a  
median of 56 days after the first examination. In a retrospective case series by Smith et 
al. (2005a) no pain relief after intra-articular methylprednisolone acetate or 
triamcinolone hexacetonide injection was noted in horses with talocalcaneal 
osteoarthritis. 
    In dogs corticosteroid injections are less commonly used than in horses as they are 
usually reserved for cases where severe end stage osteoarthritis does not respond to 
other treatment options and the animal is suffering considerably (Henrotin et al. 
2005).  Systemic  corticosteroids  are  not  used  in  the  management  of  human  
osteoarthritis and they are not recommended to be used in the treatment of canine 
osteoarthritis, either (Schulz 2007; Ara & Alam 2011).  
       In horses intra-articular corticosteroids are commonly used in combination with 
hyaluronic acid which might be protective against the side effects of corticosteroids 
and allow the reduction of the dose of corticosteroids (van Wereen & de Grauw 2010; 
McIlwraith 2011). Despite this practice being based more on tradition rather than 
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scientific evidence, it is quite popular among equine practitioners (van Wereen & de 
Grauw 2010; McIlwraith 2011). 
 
? In human medicine 
 
In human medicine intra-articular corticosteroid injections have been routinely 
administered to treat joint pain since the 1950s (Lavelle et al. 2007). In the treatment 
of human osteoarthritis intra-articular corticosteroids are generally used as a 
treatment adjunct after the initial recommended treatment options such as the non-
pharmacological and pharmacological therapies, mostly NSAIDs, have been tried and 
found inadequate (Douglas 2012). 
     In humans, the scientific evidence on the efficacy of intra-articular corticosteroid 
injections  in  the  treatment  of  osteoarthritis  is  strong  (Cheng  et  al.  2012).  However,  
corticosteroids have been shown to be most effective in those joint problems where 
inflammation is the most important component of the disease such as rheumatoid 
arthritis  and  juvenile  idiopathic  arthritis  (Habib  et  al.  2010).  In  most  cases  of  
osteoarthritis the articular degeneration is a more important component of the 
disease than inflammation (van Wereen & de Grauw 2010). Thus corticosteroids are 
not recommended to be used as the sole therapy for patients with chronic and stable 
osteoarthritis (Ara & Alam 2011; Douglas 2012). The long-term benefits of 
corticosteroids have also not been confirmed (Colen et al. 2010; Kon et al. 2012). 
However, corticosteroids can be very useful in the acute exacerbations of 
osteoarthritis that are seen as local inflammation with joint effusion as they have the 
potential  to  suppress  the  inflammation  rapidly  and  effectively  (Ara  &  Alam  2011;  
Douglas 2012).  
     This effect, however, seems to be only temporary. According to the meta-analysis of 
trials  comparing  hyaluronic  acid  with  corticosteroids  in  the  management  of  human  
osteoarthritis performed by Bannuru et al. (2009) corticosteroids appear to be more 
effective for pain reduction up to 4 weeks after treatment, but by and after 8 weeks 
the relative effects of hyaluronic acid products were shown to be greater.   
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2.1.3. Dosing 
 
Generally, the long-acting corticosteroid preparations, such as methylprednisolone 
acetate, triamcinolone acetonide and triamcinolone hexacetonide, are preferred for 
the intra-articular use (Innes 2012). Of these, methylprednisolone acetate (Depo-
Medrol®) is licenced for intra-articular use in dogs in Finland (Lääketietokeskus 2013). 
In addition to methylprednisolone acetate, also triamcinolone acetonide has an 
approval  from  the  United  States  Food  and  Drug  Administration  (FDA)  for  the  intra-
articular use in dogs (Plumb 2011; FDA 2013).  
      In the aforementioned study on an experimental model of canine osteoarthritis by 
Pelletier et al (1994) a single injection with 20 mg of methylprednisolone acetate 
resulted in favorable results in the structural changes of osteoarthritis. This is also the 
FDA-approved dose and the dose recommended for a large joint space by the 
manufacturer of Depo-Medrol vet® (FDA 2013; Lääketietokeskus 2013). Although 
methylprednisolone acetate is used in the intra-articular treatment of osteoarthritis of 
the knee in human medicine, in equine practice methylprednisolone acetate is 
generally not recommended to be used in high-motion joints such as the stifle and 
carpal joints, due to its potential harmful effects on articular cartilage demonstrated in 
equine studies (McIlwraith 2010; McIlwraith 2011; Cheng et al. 2012). 
     The FDA-approved dose for the intra-articular administration of triamcinolone 
acetonide in dogs is 1,0-3,0 mg as a single injection, although it can be repeated after 3 
to  4  days  if  clinical  signs  are  severe  or  the  clinical  response  is  poor  (FDA  2013).  
Triamcinolone acetonide is commonly used in equine practice and it is recommended 
for the use in high-motion joints (McIlwraith 2011; Plumb 2011). 
     In the study by Pelletier et al. (1989) the dose for triamcinolone hexacetonide was 5 
mg and the injection was repeated after four weeks. Triamcinolone hexacetonide is 
not currently approved in Finland or by FDA for the intra-articular use in canine 
osteoarthritis. However, in a review on the knee injections for the treatment of human 
osteoarthritis by Cheng et al. (2012), triamcinolone hexacetonide was considered more 
effective than triamcinolone acetonide.  
     Although there are numerous publications on the use of intra-articular 
corticosteroids in the knee osteoarthritis in human medicine, the amount and quality 
of the current data is not considered to be enough for drawing any conclusions about 
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the most efficacious agent, or the dose and dosing frequency (Douglas 2012). There 
are also only few randomized controlled studies directly comparing the efficacy of 
different intra-articular corticosteroids between each other (Douglas 2012). The 
problem is the same in the equine practice (McIlwraith 2010). The current usage 
patterns are therefore largely determined by the opinions of the practitioners (Douglas 
2012). There are currently no official guidelines for the dosages of intra-articular 
corticosteroids for the use in canine osteoarthritis, either. 
     Some recommendations regarding the injection frequency of intra-articular 
corticosteroids exist in humans and the same guidelines have been thought to be 
adaptable also to small animal medicine (Innes 2012). As there is concern about the 
potential harmful effects of intra-articular corticosteroids on the articular cartilage, a 
sufficient time period, such as at least 6-12 weeks, is generally recommended be left 
between the injections of the same joint and the same joint should not be injected 
more than 2-4 times a year (Fox & Stephens 2010; Douglas 2012; Innes 2012). On the 
other hand, some authors do not recommend to repeat an injection if the first one did 
not demonstrate any effect (Douglas 2012). 
      
2.1.4. Potential risks 
The intra-articular use of corticosteroids is also associated with potential side-effects 
(Douglas 2012; Innes 2012). Among the most notable of these is their potentially 
destructive effect on articular cartilage as intra-articular corticosteroids have been 
shown to depress chondrocyte metabolism and diminish proteoglycan and collagen 
synthesis (Schulz 2007; Douglas 2012; Innes 2012; Kon et al. 2012). As mentioned 
earlier, especially the safety of methylprednisolone acetonide has been questioned 
based  on  studies  in  horses  (McIlwraith  2010;  McIlwraith  2011).  On  the  other  hand,  
some evidence exists that lower dosages of corticosteroids might actually be 
chondroprotective and delay the progression of cartilage lesions (Kon et al. 2012). An 
elevated risk of weakening of the ligaments of the injected joint has also been 
associated with repeated intra-articular corticosteroid injections (Colen et al. 2010). 
Thus, in humans corticosteroids are not recommended to be injected into joints with 
instability (Philipose et al. 2011). 
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    An elevated risk of infection, especially with repeated injections, has also been 
associated  with  corticosteroid  injections  (Colen  et  al  2010).  To  reduce  the  risk  of  
introducing pathogens into the joint cavity, strict aseptic technique must be followed 
like in all cases of intra-articular injections (Innes 2012). In addition to this some equine 
practitioners routinely use intra-articular antibiotics with corticosteroid injections (van 
Wereen & de Grauw 2010). Systemic bacteremia, suspected septic arthritis or infection 
of the overlying soft tissues are absolute contraindications for intra-articular 
corticosteroid injections (Lavelle et al. 2007; Philipose et al. 2011). 
     Intra-articular corticosteroids can cause synovitis without microbial infection. This 
reactive synovitis following a corticosteroid injection, also known as the steroid flare, 
has been documented in horses and humans with a prevalence of 2-6% in humans 
(Lavelle  et  al.  2007;  Edwards 2011).   It  is  believed to be a form of  chemical  synovitis  
caused by the injected crystals (Lavelle et al. 2007). 
   There are reports on human patients that the absorption of intra-articularly 
administered corticosteroids into systemic blood circulation has resulted in systemic 
side-effects (Habib 2009). As intra-articular corticosteroids have been shown to cause 
an increase in the blood glucose levels for a few days after the injection, some concern 
has been raised regarding their use in patients with diabetes (Lavelle et al. 2007; Habib 
2009). Intra-articular steroids have also been shown to affect the hypothalamic-
pituitary-adrenal axis transiently resulting in a reduction in serum cortisol levels that 
typically  normalize in a  few days (Lavelle  et  al.  2007).   It  is  also noteworthy,  that  the 
use of corticosteroid injections is contraindicated in pregnant animals (FDA 2013, 
Lääketietokeskus 2013). 
      Despite the potential risks, most human studies on corticosteroids indicate that 
when used judiciously their benefits exceed the potential risks (Innes 2012). However, 
clinical studies specially focusing on the progression of osteoarthritis after 
corticosteroid injection are still needed (Kon et al. 2012). 
 
2.2. HYALURONIC ACID 
2.2.1. Mechanism of action 
Hyaluronic  acid  (HA,  hyaluronan)  is  a  polysaccharide  that  consists  of  a  long  chain  of  
disaccharides (???-glucuronyl- ???-N-acetylglucosamine) (Henrotin et al. 2005). 
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Endogenous hyaluronic acid produced by the type B synoviocytes and fibroblasts has 
an important function as it is largely responsible for the shock-absorbing and 
lubricating properties of the synovial fluid (Henrotin et al 2005; Bannuru et al. 2009; 
Gomis et al 2009; Kwon & Park 2012). 
      Intra-articular hyaluronic acid injections are widely used in human medicine despite 
the fact that their mechanism of action is not completely understood (Evans 2005). In 
osteoarthritis the concentration and molecular weight of hyaluronic acid are markedly 
reduced due to fragmentation and insufficient production (Henrotin et al. 2005; 
Venable et al. 2008; Gomis et al. 2009; Kwon & Park 2012). This interferes with the 
physiological functions of synovial fluid as the decreased lubrication increases the 
stress  upon  the  diseased  cartilage  leading  to  further  cartilage  damage  (Kwon  &  Park  
2012). Viscosupplementation with exogenous hyaluronic acid is aimed at restoring the 
viscoelasticity of synovial fluid and reducing the pain associated with the joint 
movement (Henrotin et al. 2005; Larsen et al. 2008; Gomis et al. 2009; Kwon & Park 
2012). 
     In addition to the mere restoration of the elastic and viscous properties of synovial 
fluid, studies indicate that hyaluronic acid might also have other mechanisms of action 
and identifying other biological properties of hyaluronic acid has been attempted 
(Evans 2005; Abate et al. 2012). Potential anti-inflammatory, anti-nociceptive and 
chondroprotective properties of hyaluronic acid have been suggested, although mostly 
based on in vitro studies (Colen et al. 2010; Edwards 2011).  
     Possible chondroprotective modes of action in addition to restoration of the 
synovial fluid elastoviscosity include the promotion of endogenous hyaluronic acid 
production, stimulation of chondrocyte matrix component synthesis and inhibition of 
chondrocyte matrix metalloproteinase synthesis (McNeil 2011). The anti-inflammatory 
effect is thought to be caused by decreased migration of inflammatory cells and 
lowered levels of inflammatory mediators such as prostaglandin E2 and bradykinin. 
(Abate  et  al.  2012)   In vitro studies also suggest that hyaluronan might enhance 
cartilage matrix synthesis, blunt responses to IL-1, prevent damage caused by oxygen-
derived free radicals, inhibit phagocytosis and protect chondrocytes from apoptosis 
(Evans 2005; Schulz 2007). Hyaluronic acid of higher molecular weight has also been 
shown to inhibit the hyaluronic acid degradation (Caron 2005; Abate et al. 2012;Kwon 
& Park 2012). 
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     The analgesic effect of intra-articular hyaluronan has been proposed to be caused at 
least partly by the inhibition of the pain receptors, reduction of the sensitivity of 
synovial nerve endings and stimulation of synovial lining cells (Caron 2005; Evans 2005; 
Abate et al. 2012). 
     It  is  yet  to  be  explained  why  the  maximal  clinical  effect  of  hyaluronic  acid  occurs  
several weeks after the injection and persists for a relatively long time, despite the fact 
that the injected hyaluronic acid is cleared from the joint space in less than a day 
(Evans  2005;  Colen  et  al.  2010).  One  of  the  theories  to  explain  this  is  that  the  
supplemented hyaluronic acid induces the synthesis of the endogenous hyaluronic acid 
(Evans 2005). Although the half-life of hyaluronic acid in the joint space is remarkably 
shorter than its duration of clinical effect, hyaluronic acid is currently still classified as a 
viscosupplement and not as a biologic therapy (Waddell 2007; Schulz 2007; Edwards 
2011). 
      There are several different hyaluronic acid preparations of different molecular 
weight, concentration and origin commercially available (Evans 2005). Common 
sources of exogenous hyaluronic acid are the rooster comb and bacterial fermentation 
(Evans 2005; Kon et al. 2012). The molecular weight of the commercially available 
hyaluronic acid preparations is generally somewhat smaller than that of the 
endogenous hyaluronic acid (Edwards 2011).  Thus a cross linked hyaluronic acid 
preparation with an increased viscosity and longer half-life, known as hylan, has been 
developed (Evans 2005). 
 
2.2.2. Scientific evidence and clinical use 
? In veterinary medicine 
 
The first clinical trials on intra-articular hyaluronic acid were performed on racehorses 
when Butler et al in 1970 demonstrated that horses performed better after the 
hyaluronic acid injection (Evans 2005). Hyaluronic acid is still commonly administered 
intra-articularly for the management of osteoarthritis in horses although clinical 
studies on the effect of hyaluronic acid on horses with naturally occurring 
osteoarthritis are currently lacking (Edwards 2011; McIlwraith 2011). 
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     The scientific evidence on the efficacy of intra-articular hyaluronic acid in the 
treatment  of  naturally  occurring  osteoarthritis  in  dogs  is  scarce.   The  studies  
performed on experimental canine models of osteoarthritis have failed to demonstrate 
clear benefits of hyaluronic acid supplementation (Aragon et al. 2007; Johnston et al. 
2008; Sanderson et al. 2009). On the other hand, the quality of these studies has also 
been evaluated to be rather low in two systematic reviews (Aragon et al. 2007; 
Sanderson et al. 2009). 
      Hellström et al. (2003) compared the efficacy of intra-articular high molecular 
weight sodium hyaluronate to that of oral carprofen in 36 dogs with naturally 
occurring osteoarthritis. The dogs received two injections of sodium hyaluronate three 
weeks apart. At six weeks the lameness of the dogs had significantly improved 
compared to the carprofen group. However, the response to treatment was evaluated 
only by visual examination of lameness and no objective outcome variables were used. 
     Smith et al. (2005b) performed a study that was designed to determine whether 
intra-articular hyaluronan injections alter the progression of osteoarthritis and pain 
perception after the transection of anterior cruciate ligament in a canine model of 
osteoarthritis. The 30 dogs that were included in the study were divided into three 
study groups that received intra-articular injections once a week for the first five 
weeks after surgery and again for five weeks 13 weeks after surgery. The prophylactic 
group received hyaluronan during the first injection series and saline during the 
second series while the treatment group was given saline in the first series and 
hyaluronan in the second series. The control group received saline during both sets of 
injections. No significant differences were noted between the study groups neither in 
the ground reaction forces measured with a force platform, the arthroscopic 
examination 12 weeks after ligament transection or on the gross examination 32 
weeks after ligament transection. Histologic scores and biochemical composition of 
articular cartilage were also similar between the three groups.  
   The results from a previous study by Smith et al (2001) were also discouraging.  The 
anterior cruciate ligament of the left stifle joint of 14 dogs was transected and the dogs 
were then divided into two groups of seven dogs. In the treatment group the unstable 
knee was injected with 10 mg of hyaluronic acid once a week for five weeks starting 
the day after surgery, while in the control group the knee was injected with saline. The 
analysis of synovial fluid revealed no changes in the synovial fluid volume or in the 
44 
 
molecular weight of hyaluronic acid. The administration of hyaluronic acid also did not 
restore the synovial fluid hyaluronic acid concentration to normal levels.  
    More promising results were obtained from a study by Echigo et al. (2006) on the 
effect of intra-articular hyaluronic acid on the apoptotic chondrocytes in the articular 
cartilage after the experimental cranial cruciate ligament rupture in eight dogs. The 
number of apoptotic chondrocytes in the articular cartilage was found to be lower in 
the dogs treated with hyaluronic acid compared to the eight dogs in the control group.  
   The  results  from  the  placebo-controlled  study  by  Wenz  et  al.  (2000)  were  also  
encouraging. After the induction of osteoarthritis of twenty-seven dogs by the 
severance of the cranial cruciate ligament, the nine dogs in the treatment group were 
divided into subgroups that received four injections of hyaluronan intra-articularly 
once a week beginning either three, six or twelve weeks after the surgery. The 
specimens of articular cartilage were collected five weeks after the last injection and 
examined both macroscopically and histologically. There were found to be significantly 
less changes in the articular cartilage attributable to osteoarthritis in the joints treated 
with hyaluronic acid compared to the placebo-treated joints. The injected dose of 
hyaluronic acid was two times larger in this study than in the studies by Smith et al 
(2001 and 2005b). 
    Hyaluronic acid has been shown to possess potential beneficial effects on the 
articular  cartilage  also  in  other  experimental  models.   One  of  these  is  the  study  by  
Sagliyan et al. (2009) on the effect of using hyaluronic acid with autogenic cancellous 
grafts in the treatment of experimentally induced osteochondral defects in the canine 
stifle joints. A defect of 10 mm in depth was created on the femoral sulcus of both legs 
of 10 dogs and filled with autogenic cancellous graft. The left stifle joint was injected 
with 2 mg/kg of hyaluronic acid immediately after the operation and 1 month 
afterwards. The right stifle joints served as the control group. Half of the dogs were 
sacrificed 3 months and the rest 6 months after the surgery and the joints were 
evaluated macroscopically and histologically. In the joints injected with hyaluronic acid 
ossification process and trabeculous bone formation seemed to occur faster than in 
the control joints.  
      The use of hyaluronic acid in the management of canine osteoarthritis is not even 
nearly as established as it is in the treatment of equine osteoarthritis. In horses, 
hyaluronic acid as an only intra-articular medication is recommended mostly for cases 
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in which the synovitis is mild to moderate. However, it is usually combined with an 
intra-articular corticosteroid, as this provides a faster and more effective response to 
treatment. Another benefit of the combined use is that hyaluronic acid might decrease 
the risk of potential side effects of intra-articular corticosteroids. (McIlwraith 2011). 
 
? In human medicine 
 
The first studies on the use of hyaluronic acid in the management of human knee 
osteoarthritis were carried out in the 1970s (Migliore & Granata 2008). Unlike in dogs, 
there are clinical studies and meta-analyses confirming the efficacy of hyaluronic acid 
in the management of human patients with osteoarthritis (Edwards 2011; Iannitti et al. 
2011). For example, in a study performed by Huang et al (2011) five weekly injections 
of 500-730 kDa sodium hyaluronate resulted in significantly greater improvement in 
the pain score from baseline to week 25 in two hundred human patients with knee 
osteoarthritis compared to a placebo group. 
     On the other hand, contradictory results have also been reported and the 
conclusions of certain clinical studies and meta-analyses have varied between dramatic 
improvements to no beneficial effect (Evans 2005; Colen et al 2010). The placebo 
effect and the differences between different hyaluronic acid preparations may explain 
some  of  the  discrepancies  found  in  the  literature  (Evans  2005).  The  blinding  is  also  
particularly challenging when injecting hyaluronic acid because it is easily recognized 
due to its high viscosity (Evans 2005). Thus it is recommended, that in the studies on 
the effects of hyaluronic acid, the treating physician and the outcome observer are not 
the same person (Evans 2005). 
     Currently intra-articular hyaluronic acid therapy is recommended for those human 
patients that have not responded to standard non-pharmacologic and pharmacologic 
treatment options or that have contraindications for NSAID use or surgical treatment 
(Waddell 2007; Kwon & Park 2012). Compared to intra-articular corticosteroids, 
hyaluronic acid is usually considered as the second-line option in cases where 
corticosteroid injections have not provided adequate treatment response (Kwon & 
Park 2012).  There is some evidence that the pain-relieving effect of hyaluronic acid is 
longer than that of the corticosteroids but corticosteroids are still preferred over 
hyaluronic acid in cases of acute inflammation (Waddell 2007; Ara & Alam 2011; Kwon 
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& Park 2012). One should also bear in mind that the hyaluronic acid preparations are a 
lot more expensive than corticosteroids (Ara & Alam 2011). 
     Despite the lack of firm conclusions about the clinical efficacy of intra-articular 
hyaluronic acid injections, the treatment continues to be very widely used in humans 
in the absence of competing options (Evans 2005). 
 
2.2.3. Dosing 
There are no official guidelines on dosing and frequency of administration for the use 
of intra-articular hyaluronic acid in dogs. Also, currently none of the hyaluronic acid 
products on the market in Finland or in the United States has an approval for the intra-
articular use in canine osteoarthritis (Lääketietokeskus 2013; Plumb 2011). 
     In the aforementioned studies by Smith et al (2005b) and Smith et al (2001) on the 
experimental canine models of osteoarthritis, the dose of hyaluronic acid was 10 mg 
given to dogs once a week for 5 consecutive weeks. The dogs in these studies weighed 
20-30 kg. However, as stated earlier, the results from these studies were not 
particularly encouraging. In the study by Wenz et al. (2000) the dose of hyaluronic acid 
was 20 mg given to the stifle joints of foxhounds weighing 26-32 kg.  
    When used as an adjunctive treatment for canine synovitis, the recommended dose 
has been remarkably lower, as only 3-5 mg of high molecular weight hyaluronan at 
weekly intervals has been suggested (Plumb 2011). 
   An example of a recommended clinical treatment regime in horses is a series of four 
to five hyaluronan injections at 7- to 14-day intervals (Caron 2005).  In the treatment 
of  human  knee  osteoarthritis  hyaluronic  acid  is  typically  given  once  a  week  for  3-5  
weeks (Evans 2005; Strauss et al. 2009). 
 
2.2.4. Potential risks 
Intra-articular hyaluronic acid is commonly used and safe and there are no specific 
contraindications for its use, other than those for intra-articular injections in general 
(Baltzer  et  al  2009;  Plumb  2011).  No  adverse  effects  were  mentioned  in  the  
aforementioned studies on dogs, either (Smith et al. 2001; Smith et al. 2005b). 
   Most of the reported side effects have been local, for example local heat, swelling 
and effusion (Plumb 2011; McNeil 2011). Usually these symptoms subside within 24-48 
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hours and require no treatment (Plumb 2011). In addition to these, allergic reactions 
have also been reported rarely in humans (Evans 2005). The incidence of adverse 
effects has been reported to be more common when using chemically cross-linked 
preparations (hylan) (Evans 2005; McNeil 2011). 
 
2.3. THERAPIES TARGETED AT THE BIOLOGICAL MECHANISMS OF 
         OSTEOARTHRITIS 
 
As the role of biological mechanisms in the pathogenesis of osteoarthritis was 
recognized only three decades ago, the idea of affecting the biologic mechanisms 
involved in osteoarthritis is also relatively new. Only in the last decade has there been 
any serious attempt to develop therapy options to affect the cellular mechanisms of 
the disease process. (Evans 2005.)  
    The  goal  in  the  field  of  biologically  based  therapies  is  to  develop  a  treatment  
modality with regenerative action that would provide both anabolic and anti-catabolic 
activities (Textor 2011). Developing means to affect the receptors and signaling 
pathways  of  the  cytokines  and  growth  factors  involved  in  the  disease  process  or  to  
control directly the expression of the responding genes is also under research (Evans 
2005).  
     The use of cytokine inhibitors and growth factors in the treatment of osteoarthritis 
was  first  proposed  in  the  late  1970s  and  early  1980s  (Wehling  et  al.  2007).  The  
rationale behind these therapies is based on the current opinion that there is an 
imbalance in the production of the pro-inflammatory and anti-inflammatory cytokines 
(Sampson et al. 2010). Thus, therapies that would reduce the effects or production of 
the pro-inflammatory cytokines, especially IL-1 and TNF-?, or that would be a source of 
anabolic factors such as growth factors, could potentially alter the course of the 
disease (Evans 2005; Calich et al. 2010; Fox & Stephens 2010). 
     Currently the anti-cytokine treatment options targeted at IL-1 are the 
administration of interleukin-1 receptor antagonist (IL-1Ra) and Diacerein (Calich et al. 
2010).  IL-1Ra  can  be  administered  either  via  autologous  blood  products,  such  as  
autologous conditioned serum, or as a synthetic form, known as anakinra that is used 
in  the  treatment  of  rheumatoid  arthritis  in  humans  (Evans  2005;  Calich  et  al.  2010;  
Textor 2011). IL-1Ra has also been administered through gene transfer in an equine 
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model of osteoarthritis and in human medicine (Frisbie et al. 2007). Diacerein is not 
administered intra-articularly and the use of anakinra has not been studied on dogs, so 
they will not be discussed here. Adalimumab, which is an inhibitor of TNF-?, will also 
be left out of the review due to the lack of studies in veterinary medicine.   
     The main ways of growth factor administration are currently autologous blood 
injection (ABI) and platelet-rich plasma preparations (Creaney et al. 2011). As studies 
on the use of whole blood in the management of osteoarthritis are lacking, only the 
use of platelet-rich plasma will be discussed in the following section. 
     The use of autologous blood products has been increasing as they might provide 
cellular and humoral mediators to enhance healing in tissues with low healing 
potential (Filardo et al. 2012). There are several methods of concentrating blood 
derived growth factors and other potentially beneficial cytokines including platelet rich 
plasma (PRP), autologous conditioned serum (ACS) and autologous blood injection (Fox 
&  Stephens  2010;  Leong  et  al.  2012).  Although  PRP  and  ACS  are  both  derived  from  
whole blood, their mechanisms of action are different (Textor 2011). The differences 
between these two methods will be discussed later.  
     The clinical use of autologous blood products both in veterinary and human 
medicine has already started. However, one should note that as the use of autologous 
biologic therapies is not limited by the restrictions and testing required for 
pharmaceuticals and as their use in general is very safe, it has been suggested that 
enthusiasm might have outpaced the scientific evidence of their effects.  (Stief et al. 
2011.) 
 
2.3.1. Mesenchymal stem cells 
2.3.1.1. Mechanism of action 
 
Stem cells are defined as undifferentiated cells with the ability to convert into 
differentiated cells and to regenerate tissues (Mafi et al. 2011; Fortier & Tuan 2012). 
The three main classes of stem cells are the embryonic stem cells, fetal stem cells and 
adult  stem  cells  (Fortier  &  Tuan  2012).  The  adult  stem  cells,  such  as  mesenchymal,  
neural and hematopoietic stem cells, are responsible of the normal tissue maintenance 
(Mafi et al. 2011; Punwar & Khan 2011; Gattegno-Ho et al. 2012; Fortier & Tuan 2012). 
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    Currently most of the clinical attention has focused on the mesenchymal stem cells 
(MSCs) that have the potential to differentiate into the cells of mesenchymal origin, 
such as chondrocytes, osteoblasts, adipocytes and fibroblasts (Mafi et al. 2011; 
Gattegno-Ho et al. 2012). They can be harvested from a variety of sources, the most 
common of which are the bone marrow (BM-MSCs) and adipose tissue (AD-MSCs) 
(Black et al. 2007; Gutierrez-Nibeyro 2011). 
     According to the systematic review of studies on human patients performed by Mafi 
et  al  (2011)  BM-MSCs  seem  to  have  a  higher  differentiation  potential  than  MSCs  of  
other origin. However, there are certain benefits of choosing AD-MSCs over BM-MSCs. 
The relative ease and repeatable access to subcutaneous tissue together with the 
simple isolation procedure are some of these (Black et al. 2007; Punwar & Khan 2011). 
Also, harvesting of the bone marrow is painful and includes potential risks (Punwar & 
Khan  2011).  In  dogs  bone  marrow  aspirates  are  most  commonly  obtained  from  the  
proximal humerus, proximal femur or tuber coxae (Fortier & Travis 2011). Adipose 
tissue in dogs has been collected from the abdominal, thoracic and inguinal areas ad 
from the region of the falciform ligament (Black et al. 2008). 
    The mechanism of action of MSC therapy is not completely understood, but the 
researchers believe that there are likely to be multiple receptors or pathways involved 
(Black et al. 2007). Currently it is not clear whether MSCs can differentiate into tissue-
specific cells or is their potential therapeutic effect mediated through the secretion of 
immunomodulatory and trophic factors such as the cytokines and growth factors that 
affect  the  surrounding  cells  and  alter  the  local  inflammatory  responses  (Black  et  al.  
2008; Fortier & Travis 2011; Fortier & Tuan 2012). MSCs might also recruit other 
endogenous cells to the site of the lesion (Black et al. 2007). 
     The isolation process of AD-MSCs includes mincing and washing, followed by 
collagenase digestion and centrifugation (Black et al. 2007). The pellet formed after 
the centrifugation, known as the stromal vascular fraction (SVF), contains in addition 
to  AD-MSCs  a  diverse  group  of  other  cells  such  as  fibroblasts,  pericytes,  circulating  
blood cells and endothelial cells (Black et al. 2007; Black et al 2008). This stromal 
vascular fraction is added into a solution and this suspension is injected back into the 
patient (Davatchi etl al. 2011). 
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2.3.1.2. Scientific evidence and clinical use 
 
? In veterinary medicine 
 
The most common clinical application of stem cells in clinical veterinary medicine is the 
treatment  of  musculoskeletal  problems  in  horses  and  dogs  (Fortier  &  Travis  2011).  
Autologous MSC therapy, meaning the use of the patient’s own MSCs as a source, is 
already available for veterinary patients in certain countries (Black et al. 2007; Black et 
al.  2008).  However,  as  the  use  of  stem  cells  in  veterinary  patients  is  not  closely  
supervised by any organization due to their so-called minimally manipulated nature, 
some researchers suggest that there might be clinical use of certain therapies with no 
shown efficacy in preclinical animal studies or in vitro (Fortier & Travis 2011). 
    Early results suggest that AD-MSC therapy might be useful as a treatment adjunct in 
the management of canine osteoarthritis. The only randomized, blinded, placebo-
controlled clinical trial investigating the effect of stem cell therapy on canine hip 
osteoarthritis was performed by Black et al (2007). In this study 18 dogs with bilateral 
coxofemoral joint osteoarthritis received intra-articularly either 4,2-5 million viable 
stem cells prepared from the dog’s own fat tissue or a similar volume of phosphate 
buffered saline. Statistically significant improvements in lameness and in pain and in 
the range of motion of the treated joint were seen in the treatment group compared 
both  to  the  control  group  and  to  the  baseline.  However,  no  objective  outcome  
variables were used in this study. 
    Black  et  al  (2008)  performed  also  a  pilot  study  to  evaluate  the  clinical  effect  of  a  
single intra-articular injection of AD-MSCs in 14 dogs with osteoarthritis of the elbow 
joint. In this study a statistically significant improvement from baseline was 
demonstrated in the orthopedic examination scores and owner scores. However, this 
study was not placebo-controlled. 
     MSC therapy has also been studied in horses. Frisbie et al (2009) studied the clinical, 
biochemical and histologic effects of intraarticularly administered adipose-derived 
stromal vascular fraction or bone marrow-derived MSCs in an equine model of 
osteoarthritis. Twenty-four horses were divided into three study groups of eight 
horses. The horses in the control group received placebo while the horses in the two 
study groups received either adipose-derived stromal vascular fraction or bone 
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marrow-derived mesenchymal stem cells into the middle carpal joint. Although the 
levels of prostaglandin E2 decreased in the synovial fluid, no significant improvements 
were demonstrated in the clinical or histopathological examination.  
   Based on the unremarkable results of the aforementioned study and the lack of 
other studies proving MSCs to have any effect on osteoarthritis, MSC therapy is 
currently not generally recommended to be used as a part of osteoarthritis treatment 
in the equine practice (McIlwraith 2011). 
 
? In human medicine 
 
In human medicine MSCs have been shown to have potential in the treatment of 
musculoskeletal disorders such as osteonecrosis of the femoral head, osteogenesis 
imperfecta, degenerative disc disease and Duchenne muscular dystrophy (Mafi et al. 
2011). 
     The effect of MSC therapy on osteoarthritis has also been studied in humans. 
Davatchi et al (2011) examined the use of bone marrow-derived MCSs on four human 
patients with knee osteoarthritis. There were modest improvements in the pain 
scores, in physical examination and in the range of motion of the treated joint. 
      The study performed by Emadedin et al. (2012) evaluated the effects of intra-
articular injection of bone marrow-derived autologous mesenchymal stem cells in six 
patients requiring joint replacement surgery due to knee osteoarthritis. The main 
objective of the study was to evaluate the safety of the treatment. Other parameters 
such as pain, functional status of the knee and walking distance were also evaluated 
and  were  shown  to  improve  up  to  six  months  after  the  injection.  An  increase  in  the  
cartilage thickness, extension of the repair tissue over the subchondral bone and a 
decrease in the size of edematous subchondral patches was noted in three of the 
patients. No adverse effects were noted. 
      In human medicine the MSC therapy is currently not a part of the routine 
treatment regimen of patients with osteoarthritis. Before the wide clinical use of MSCs 
can be recommended, further studies are needed, as little is currently known of the 
cellular characteristics and endogenous functions of MSCs. (Mafi et al. 2011.) 
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2.3.2. Autologous conditioned serum 
2.3.2.1. Mechanism of action 
Catabolic cytokine interleukin 1 (IL-1) is the most potent known mediator of cartilage 
breakdown and it is a major inflammatory mediator in joint diseases (Frisbie et al. 
2007; Baltzer et al. 2009). Interleukin 1 receptor antagonist (IL-1Ra) prevents the 
interaction of IL-1 with the cell surface receptors thus blocking the inflammatory 
cascade initiated by IL-1 (Baltzer et al. 2009; Chevalier & Kemta-Lepka 2010; Textor et 
al. 2011). However, there are thousands of IL-1 receptors on the surface of every 
fibroblast and yet bonding of only a few of them is enough to induce the cellular 
responses to IL-1 (Textor 2011). Therefore, to prevent the effect of IL-1, the ratio of IL-
1Ra to IL-1 must be quite high (Textor 2011). 
    Autologous conditioned serum is one of the new biological therapies that have 
emerged as potential treatment options for human and equine osteoarthritis (Hraha et 
al.  2011).  This  therapy  was  developed  in  the  mid-1990s  in  an  attempt  to  create  an  
injectable material that would be rich in endogenous IL-1Ra (Baltzer et al. 2009). ACS is 
considered as the endogenous source of IL-1Ra, since the major natural source of IL-
1Ra are the blood monocytes (Evans 2005; Fox & Stephens 2010). Different methods 
to stimulate their IL-1Ra-production have been developed (Evans 2005).  
     Most commonly ACS is produced by incubating venous blood with medical grade 
class beads which induces the peripheral blood leukocytes to produce elevated 
amounts of endogenous anti-inflammatory cytokines such as IL-1Ra, IL-4, IL-10 and 
growth factors such as fibroblastic growth factor-1, hepatocyte growth factor and 
transforming  growth  factor-?1  (Frisbie  et  al.  2007;  Rutgers  et  al.  2010).  These  anti-
inflammatory cytokines and growth factors accumulate in the serum which is then 
harvested as the therapeutic agent (Wehling et al. 2007; Rutgers et al. 2010; Hraha et 
al. 2011). After centrifugation and extraction, ACS can be either stored for later use or 
injected into the lesion site (Wehling et al. 2007). 
    Despite the already ongoing clinical use, the exact mechanism of action of ACS in the 
osteoarthritic joint is not yet fully understood (Rutgers et al. 2010). Even the data 
available on the actual composition of the conditioned serum is limited (Rutgers et al. 
2010). Because the stimulation increases the concentration of IL-1Ra to concentrations 
of as much as 140-fold greater than other anti-inflammatory proteins found in ACS, IL-
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1Ra is assumed to be one of the major mediators behind the clinical improvement in 
patients with osteoarthritis (Frisbie et al. 2007; Hraha et al. 2011). 
    However,  ACS  is  not  purified  IL-1Ra,  as  it  also  contains  many  blood-derived  
substances and its effects are stronger and longer-lasting than what researchers think 
could  be  expected  from  a  short  series  of  injections  containing  merely  IL-1Ra  (Evans  
2005; Textor 2011). Thus some researchers suggest that the clinical effects are caused 
by the synergistic effect of all factors in the ACS (Wehling et al. 2007).  
     As  the  efficacy  of  ACS  is  currently  based  merely  upon  the  improvement  in  clinical  
signs and symptoms, the possible disease-modifying effects that could occur in 
response to the presence of growth factors are yet to be determined. (Evans 2005.) 
 
2.3.2.2. Scientific evidence and clinical use 
 
? In veterinary medicine 
 
Commercial ACS therapies are currently not available for dogs, but for horses ACS 
therapy, also known as the IL-1Ra protein (IRAP) therapy, is available also in Finland 
(Wehling et al. 2007; Fox & Stephens 2010).  In horses, the most common clinical 
application of ACS is the intra-articular treatment of osteoarthritis (Textor 2011; 
Baltzer et al. 2009). In horses it has also been used in some cases prophylactically after 
arthroscopy for its potential anti-inflammatory and chondroprotective effects (Textor 
2011). 
    Studies on dogs are currently lacking, but the effects of ACS therapy have been 
studied on equine models of osteoarthritis. Frisbie et al (2007) evaluated the clinical, 
biochemical and histologic effects of intra-articularly administered ACS compared to a 
placebo in an equine model of osteoarthritis. Osteoarthritis was induced in the middle 
carpal joint of all horses. In the 8 horses that were treated once a week for four weeks 
with ACS starting 14 days after the induction of osteoarthritis, significant clinical 
improvement in lameness and also significantly decreased synovial membrane 
hyperplasia were demonstrated. Such changes were not seen in the eight placebo-
treated horses.  
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? In human medicine 
 
In humans ACS is marketed as Orthokine (Orthogen AG, Dusseldorf, Germany) that has 
been available for clinical use since 1998 in several European countries (Baltzer et al. 
2009;  Fox  &  Stephens  2010).  In  human  medicine  it  is  used  in  the  treatment  of  
osteoarthritis, lumbar pain of neurogenic origin and muscle injuries (Wehling et al. 
2007; Textor 2011). 
    In the Orthokine method approximately 50-60 ml of peripheral blood is drawn into 
the special syringes containing medical-grade class beads and is incubated for 24 hours 
(Fox & Stephens 2010; Evans 2005). After the separation from the blood cells, the 
conditioned serum is collected by centrifugation and filtering (Evans 2005). This serum 
is then returned to the patient in a series of up to six intra-articular injections given at 
weekly intervals (Evans 2005). 
    The effects of ACS therapy have been studied on humans. The randomized, placebo-
controlled  double-blind  clinical  trial  by  Baltzer  et  al  (2009)  compared  the  effects  of  
intra-articularly administered ACS to hyaluronan and saline in 376 human patients with 
knee osteoarthritis. A reduction in pain was noted in all study groups, but the effects 
of ACS were superior to those of hyaluronic acid and saline. No differences between 
the effects of hyaluronic acid and saline were demonstrated. In addition to this, the 
therapeutic effect seemed to be rather long-lasting: there were still statistically 
significant differences between the ACS group and the two other study groups at a 
follow-up  performed  2  years  after  the  initial  study.  No  serious  side-effects  of  ACS  
administration were noted during the observation period.   
    Although ACS therapy seems generally a safe and treatment option, further studies 
are required to confirm its efficacy in the treatment of osteoarthritis (Wehling et al. 
2007; Fox & Stephens 2010).  
 
2.3.3. Platelet-rich plasma  
2.3.3.1. Mechanism of action 
 
As the first cell type to arrive at the site of injury platelets take part in the early phases 
of  inflammation  and  in  maintaining  the  healing  process  (Cole  et  al.  2010;  Kon  et  al.  
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2011). Originally platelets were thought to act merely in the clotting process, but they 
also contain growth factors and cytokines that are crucial in the soft tissue healing and 
bone mineralization (Sampson et al. 2010). Many of the bioactive proteins released by 
platelets have been shown to attract the macrophages, mesenchymal stem cells and 
osteoblasts that play a role in tissue regeneration and healing (Sampson et al. 2010). 
     The use of autologous growth factors especially in the treatment of musculoskeletal 
injuries has recently received plenty of attention (Kon et al. 2010; Kisiday et al. 2012). 
There is scientific interest in the effects of the growth factors especially on 
osteoarthritis and cartilage repair because of their ability to recruit chondrogenic cells, 
stimulate proliferation and enhance synthesis of cartilage matrix (Kon et al. 2010; 
Spakova et al. 2012). 
     Growth factors stored in the platelets such as platelet-derived growth factor (PDGF), 
transforming growth factor ?1 (TGF-?1), insulin-like growth factor 1 (IGF-1), vascular 
endothelial growth factor (VEGF), basic fibroplastic growth factor (bFGF) and 
epidermal growth factor (EGF), have been shown to take part in the regulation and 
synthesis  of  the  articular  cartilage  (Cole  et  al.  2010;  Kon  et  al.  2011a  ;  Filardo  et  al.  
2012). Platelets are also a source of cytokines, chemokines and other proteins that 
take part in the stimulating of chemotaxis, cell proliferation and maturation, 
modulation of inflammatory molecules and the attraction of leukocytes (Kon et al. 
2011a). Other substances stored in the platelets such as metalloproteinases, 
antibacterial and fungicidal proteins, coagulation factors, calcium ions, serotonin and 
dopamine can also have an effect on the inflammation and tissue regeneration (Cole et 
al. 2010; Kon et al. 2011a; Filardo et al. 2012). 
     It has been thought, that the delivery of high concentrations of platelets would lead 
to the delivery of high concentrations of the aforementioned growth factors as well 
and thus have the potential to augment or stimulate the same healing process that 
normally  occurs  after  injury  (Sampson  et  al.  2010;  Stief  et  al.  2011;  Spakova  et  al.  
2012). Intra-articular administration of a platelet-rich concentrate has also been 
considered to have potential to slow down the progression of osteoarthritis by 
stimulating the cartilage anabolism (Stief et al. 2011). 
     Of the platelet-derived products available, platelet-rich plasma (PRP) is among the 
most commonly used (Textor 2011; Kisiday et al. 2012). As the name implies, platelet-
rich plasma is defined as an autologous concentration of platelets in a small plasma 
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volume  (Spakova  et  al.  2012).  Other  options  such  as  platelet-rich  fibrin  clot  (PRFC),  
platelet-rich clot releasate and platelet concentrate, are also available (Textor 2011). In 
addition to the growth factors, PRP also contains plasma proteins such as fibrin, 
fibronectin and vitronectin that act as mesenchymal cell adhesion molecules (Spakova 
et al. 2012). 
     Following the injection into the damaged tissue, the platelets of PRP begin active 
secretion  of  growth  factors  within  10  minutes  with  more  than  95  %  of  the  total  
amount  released  within  the  first  hour  (Kon  et  al.  2011a).  Although  the  secretion  of  
growth factor occurs mainly in the first hour of the injection, the platelets remain 
viable for 7 days and continue to release growth factors. Thus a single injection into 
the damaged tissue might be sufficient at least in most cases (Kon et al, 2011a; Leong 
et al 2012). 
      PRP is derived from the anticoagulated autologous blood by centrifugation that 
eliminates most of the red blood cells and concentrate platelets based on the specific 
gravities of each cell type (Foster et al. 2009; Kon et al. 2011b; Kisiday et al. 2012). The 
achieved  platelet  concentration  varies,  but  is  generally  at  least  4-5  or  even  over  10  
times higher than that of the whole blood (Kon et al. 2011b; Kisiday et al. 2012). The 
platelet concentrate is activated using calcium chloride resulting in the formation of 
platelet gel that can confine the secretion of growth factors to the chosen site (Kon et 
al. 2011b). 
     PRP can be prepared using standard blood tubes and laboratory centrifuges, but 
there are also many different commercial systems available for PRP production. Some 
of the advantages of these systems are the ease of use, rapid PRP production and 
maintenance of sterility. For horses there is even a stall-side preparation system 
available (E-PET, Pall Animal Health, Port Washington, NY, USA). (Textor 2011.) 
     The three main commercial methods of producing PRP are selective blood filtration, 
single-spinning methods and double-spinning procedures of which the two latter are 
the  most  common  ones  in  the  clinical  use  (Filardo  et  al.  2012).  The  systems  differ  in  
the initial blood volume withdrawn, in the final volume of PRP and in the final platelet 
concentration (Leong et al. 2012). There are also differences in the speed and number 
of centrifugations, in the use of anticoagulant, in the presence of other cells such as 
leukocytes  in  the  preparation,  in  the  use  of  activators  and  in  the  storage  modalities  
(Filardo  et  al.  2012;  Leong  et  al.  2012).  These  differences  in  preparation  and  
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administration make it difficult to compare the results of different studies on PRP 
challenging both in human and veterinary medicine (Textor 2011; Kon et al. 2011a). 
       
2.3.3.2.  Scientific evidence and clinical use 
 
? In veterinary medicine 
 
Platelet-rich concentrates (PRC), such as PRP have gradually started to gain attention 
in the treatment of various acute and chronic sport injuries, particularly tendon and 
ligament injuries, in both human and veterinary medicine (Stief et al. 2011; Textor et 
al. 2011). Although PRP therapy is also used to treat joint diseases in horses, there are 
currently no clinical studies on the effects of PRP therapy in the management of canine 
or equine osteoarthritis (Textor et al. 2011). 
    However,  Milano  et  al  (2010)  studied  the  effects  of  PRP  in  the  treatment  of  full-
thickness articular cartilage lesions of the stifle joint in an experimental ovine model.  
The ten sheep in the treatment group received PRP either in liquid form or together 
with fibrin glue 12 months after the procedure. On both macroscopic and histological 
evaluation the amount of repair tissue was the highest in the PRP treated joints 
compared to the five untreated animals, which might indicate that PRP has a positive 
effect on cartilage repair. 
     In horses PRP therapy is mostly used in the treatment of tendon and ligament 
injuries, in some cases in combination with the stem cells.  As PRP is intended to 
support and enhance tissue healing as an anabolic agent, in horses it is recommended 
to be used after an acute traumatic injury to musculoskeletal tissues. (Textor 2011.) 
 
? In human medicine 
       
In human medicine autologous PRP was first used in 1987 by Ferrari et al after open 
heart surgery. The first clinical study on the use of PRP to supplement cancellous bone 
graft  in  humans  was  made  in  1998  with  significant  improvements  detected  in  both  
radiologic and histologic scores of bone density. (Textor 2011; Frizziero et al. 2012.) 
    The use of PRP therapy is more established in human medicine compared to 
veterinary  medicine  as  it  is  used  in  a  wide  variety  of  different  fields  such  as  sports  
58 
 
medicine, orthopaedics, dentistry, dermatology, ophthalmology and plastic and 
maxillofacial surgery (Cole et al. 2010; Kon et al. 2011a). The use of PRP in cartilage 
repair is actually relatively new (Frizziero et al. 2012). 
     Despite the fact that the use of PRP in the treatment of tendon, ligament and bone 
injuries is being extensively studied there are currently only few studies evaluating the 
effects of PRP on articular cartilage. The dose of platelets that best stimulates cartilage 
is also yet to be determined. (Kisiday et al. 2012.) 
     Currently available clinical studies on humans support the role of PRP in the 
treatment of cartilage lesions (Filardo et al. 2012).  In the study performed by Kon et al 
(2010) investigating the effect of intra-articular PRP on human knee osteoarthritis 
statistically significant improvements were demonstrated both in pain and function 
compared to baseline. However, there was no control group in this study.  Similar 
results were demonstrated in a study performed by Sampson et al (2010) evaluating 
the effects of three intra-articular PRP injections at 4 week intervals in 14 human 
patients with primary and secondary osteoarthritis.  
     PRP might even be a challenger to hyaluronic acid as indicated by results from the 
study  by  Spakova  et  al  (2012).  In  their  study  the  effects  of  intra-articular  PRP  were  
compared to those of intra-articular hyaluronic acid in 120 human patients with knee 
osteoarthritis. The injections were given once a week on three consecutive weeks. A 
statistically significantly better improvement in the clinical signs was noted on the 
evaluation  three  and  six  months  after  the  last  treatment  in  the  group  that  received  
PRP compared to the group that received hyaluronic acid.  PRP was compared to 
hyaluronic acid also in the study by Kon et al (2011b). In this study a longer-lasting and 
greater improvement in pain and function was seen when using PRP than when using 
hyaluronic acid.  
     The absence of significant adverse effects, immune reactions and disease 
transmission  are  some  of  the  advantages  of  the  use  of  autologous  PRP  (Cole  et  al.  
2010; Filardo et al. 2012; Frizziero et al. 2012). However, there is currently no data 
available on the possible long-term adverse effects (Frizziero et al. 2012). Many of the 
studies also lack controls, have small sample sizes and do not define a standardized 
PRP preparation which makes interpreting and comparing the study results rather 
challenging (Foster et al. 2009; Kon et al 2011a). Further research on factors such as 
the harvesting methods, the ideal concentration of platelets, the amount of leukocytes 
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and growth factors in the preparations and the protocols of delivery is also needed 
(Cole et al. 2010; Leong et al. 2012).  
     Although in humans the concurrent NSAID therapy is avoided based on its potential 
inhibitory effects on platelets, some authors find this to be an unnecessary precaution 
since the platelets are delivered in an already activated state (Textor 2011). 
 
2.4. BOTULINUM NEUROTOXIN TYPE A  
2.4.1. Mechanism of action 
 
There are seven serotypes (A-G) of toxins produced by the neurotoxigenic strains of 
Clostridium bacteria.  Of  these botulinum neurotoxin A (BoNT-A) is  the most common 
serotype in clinical use. (Borodic et al. 2001.) 
    The analgesic effect of intra-muscularly administered BoNT-A is attributed to a 
reduction  in  muscle  activity  caused  by  the  inhibition  of  acetylcholine  release  at  the  
neuromuscular  junction  and  following  local  muscle  paralysis  (Borodic  et  al.  2001).  
However, BoNT-A seems also have effects beyond the neuromuscular junction, which 
is a phenomenon that was noticed when the analgesic effect of BoNT-A injection was 
found to occur earlier and to a greater degree than the decreased muscle tone (Aoki 
2003; Singh 2010). Persistent joint pain can lead to sensitization of articular 
nociceptors and release of neuropeptides such as substance P and calcitonin gene-
related peptide (CGRP) (Schaible 2006; Birklein & Schmelz 2008; Innes 2012). In studies 
performed on animal models of osteoarthritis BoNT-A has been shown to inhibit the 
release of these substances (Rapp et al. 2006; Lucioni et al. 2008).  
 
2.4.2. Scientific evidence and clinical use 
 
? In veterinary medicine 
 
Botulinum toxin is currently not in clinical use in veterinary medicine, but there are 
studies on its use on animal models. The effect of BoNT-A on canine osteoarthritis has 
been studied in a small pilot study by Hadley et al. (2010). They investigated the effect 
of intra-articularly administered botulinum toxin in five dogs with unilateral chronic 
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moderate to severe osteoarthritis of either elbow or hip joint. Twenty five IU of BoNT-
A, a dose extrapolated from human studies, of BoNT-A was injected into two elbow 
joints and three hip joints and the outcome was evaluated at 2, 4, 8 and 12 weeks after 
the injection by pressure platform gait analysis and by owner assessment. The study 
showed improved ground reaction forces in the treated limb and some improvement 
in the owner’s assessment was reported in four out of five dogs.  
     No immediate adverse effects were noted in this study, but in two of the dogs there 
was mild redness and swelling at the injection site and increased lameness during the 
first 24-48 hours after the injection. However, no systemic adverse effects were noted 
and the local reactions subsided within two days.  
     Intra-articular BoNT-A has also been studied in horses. DePuy et al (2007) 
performed a pilot study on the effect of intra-articular BoNT-A on lameness associated 
with acute synovitis in an equine model. Four experimental horses were divided into 
pairs that were given either 50 units of BoNT-A or saline into the middle carpal joints. 
Acute synovitis was induced 14 days later with equine IL-1? injection and synovial fluid 
analysis, clinical evaluation of lameness and kinematic gait analysis were performed 
the next day. On histology and cytology synovitis was observed in all horses, but the 
other horse of the BoNT-A group showed no changes in the baseline gait analysis. The 
other three horses all developed prominent forelimb lameness. However, the 
interpretation of the results and determining whether or not BoNT-A prevented the 
lameness is rather challenging due to the small sample size. No detectable adverse 
effects caused by the BoNT-A injection were noted in this study either. 
      
? In human medicine 
 
The analgesic properties of intra-muscularly administered BoNT-A are well 
documented and in humans BoNT-A has been shown to be effective for treatment of 
painful movement disorders, spasticity, myofascial pain and conditions associated with 
increased  muscle  tone,  abnormal  posture  and  pain  (Borodic  et  al  2001;  Chou  et  al.  
2010). 
     Also the effects of intra-articular BoNT-A have been studied in the treatment of 
chronic joint pain in humans.  An example of these studies is the one performed by 
Singh  et  al.  (2010)  on  the  pain-relieving  effect  of  intra-articular  BoNT-A  on  chronic  
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knee pain after total knee arthroplasty. The patients received either 100 IU of BoNT-A 
or saline as a single intra-articular injection and the outcome was assessed during the 
follow-ups  at  two,  three,  four  and  six  weeks  after  the  injection.   There  was  a  
statistically significant improvement in pain and function in the treatment group 
compared to the control group during the follow-up two months after the injection. 
Although the duration of the pain-relieving effect of BoNT-A injection was also shown 
to be longer than that of the placebo, the mean duration of the pain-relieving effect in 
the study group was only 39 days. Thus it was speculated, that a higher dose or more 
frequent administration might be needed for the clinical application of BoNT-A. 
    Mahowald et al (2009) performed two randomized controlled pilot studies to 
investigate the effect of intra-articularly administered BoNT-A on joint pain in patients 
with painful shoulder or knee joints. In both studies the decrease in pain severity 
produced by BoNT-A was significant while that caused by placebo injection was not.  
     The effect of intra-articular BoNT-A on chronic joint pain has also been investigated 
in  smaller  studies,  some  of  which  lacked  the  control  group.  Chou  et  al  (2010)  
performed a study to evaluate the therapeutic effects of intra-articular BoNT-A in 
humans with advanced knee osteoarthritis. Patients were radiographically verified 
having either stage III or IV osteoarthritis according to the Kellgren-Lawrence 
classification. Clinically significant improvement in pain and stiffness were noted at 1 
month after the first injection, but statistical significance was noted only at 3 months 
after the injection and only for the pain subscale in stage III osteoarthritis. No adverse 
effects, such as increases in joint inflammation, periarticular muscle weakness, fever or 
fatigue or changes in neurosensory testing of the lower extremities have been noted in 
the human studies performed this far (Mahowald et al. 2009; Singh et al. 2009a;Singh 
et al. 2009b; Chou et al. 2010). 
 
2.5. OTHER OPTIONS 
 
In search for the optimal treatment option for osteoarthritis, a myriad of other options 
for intra-articular therapy of osteoarthritis have been studied both in human patients 
and in animal models of osteoarthritis.  Examples of these compounds that have been 
administered experimentally are orgotein, silicone, magnesium sulfate, chondroitin 
sulfate, calcitonin, saline solution, NSAIDs, somatostatin, chloroquine, 
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mucopolysaccharide polysulfuric acid ester, lactic acid solution, thiotepa cytostatica, 
polynucleotides and prolotherapy (Edwards 2011; Hameed & Ihm 2012). However, 
since the effects of many of these have been investigated only in small uncontrolled 
studies, no definitive recommendations can yet be given regarding their use (Hameed 
& Ihm 2012). 
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DISCUSSION 
Intra-articular medications, especially corticosteroids, are used in the management of 
canine osteoarthritis, although the full extent of their use among veterinarians is not 
known. There are probably many reasons why the intra-articular medications are not 
as commonly used in dogs as they are in human medicine and in the equine practice. 
First of all, there is more scientific evidence on the efficacy of intra-articular 
medications in the treatment of osteoarthritis in human medicine as the amount of 
scientific publications on the matter is very scarce in dogs. Most of these studies are 
also performed on experimental canine models of osteoarthritis and have been 
focused on evaluating the effects of the medications on the disease progression rather 
than on the clinical signs such as pain or the degree of lameness. 
     Also, unlike in humans and in horses, arthrocentesis is not a routine procedure in 
dogs and most veterinary practitioners have not been trained to perform it. 
Arthrocentesis of the commonly affected joints, such as the hip and elbow joints, is 
most likely going to require some practice before the practitioner can perform it 
comfortably. 
      An interesting remark is that the mere removal of some of the synovial fluid is a 
short-term symptomatic treatment as such, as it helps to clear the joint from the 
altered inflammatory synovial fluid. Also, it has been speculated, if intra-articular 
injection of any agent, such as saline, could have short-term beneficial effects due to 
the dilution of the inflammatory cytokines and enzymes in the joint cavity. (Colen et al. 
2012.) 
   As a conclusion of the studies, the practitioner, in my opinion, is not likely to do 
much harm by incorporating the intra-articular corticosteroids and hyaluronic acid in 
the treatment of an osteoarthritic patient in cases where other treatment options 
have been tried and proven inadequate and euthanasia is not yet an option. In these 
cases, however, strict aseptic technique must be followed, the patient has to be 
suitable  for  anaesthesia  and  the  owner  needs  to  be  aware  of  the  lack  of  the  strong  
scientific proof of the efficacy of intra-articular medications in dogs. 
     
 
?
?
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